Search Results For:
- Search results for:
- covid 19
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Multilateral organization
Diagnostic
Commercialization
- Equitable Access | Affordable pricing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Liability | Representations & Warranties
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MSD - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Liability | Representations & Warranties
- Term & termination | Term of agreement
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Liability | Indemnification & liability
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | Exploitation of results
- Intellectual Property | Ownership of background IP
- Intellectual Property | Ownership of results
- Intellectual Property | Protection of IP
- Intellectual Property | Use of background IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
GHIAA2019\MapguideSearch Object ( [search_parameters] => Array ( [qs] => covid 19 ) [filters] => Array ( [text_search] => covid 19 ) [child_filters] => Array ( ) [agreement_args] => [provision_args] => Array ( [post_type] => provision_document [posts_per_page] => -1 [post__in] => Array ( [0] => 4808 [1] => 4807 [2] => 4806 [3] => 4805 [4] => 4804 [5] => 4802 [6] => 4801 [7] => 4800 [8] => 4798 [9] => 4797 [10] => 4796 [11] => 4661 [12] => 4147 [13] => 4601 [14] => 4148 [15] => 4223 [16] => 4222 [17] => 4221 [18] => 4220 [19] => 4219 [20] => 4218 [21] => 4217 [22] => 4216 [23] => 4215 [24] => 4214 [25] => 4213 [26] => 4212 [27] => 4210 [28] => 4209 [29] => 4205 [30] => 4204 [31] => 4201 [32] => 4200 [33] => 4161 [34] => 4159 [35] => 4158 [36] => 4157 [37] => 4156 [38] => 4155 [39] => 4154 [40] => 4153 [41] => 4152 [42] => 4151 [43] => 4150 [44] => 4149 [45] => 4146 [46] => 4141 [47] => 4140 [48] => 4139 [49] => 4138 [50] => 4137 [51] => 4136 [52] => 4135 [53] => 4134 [54] => 4133 [55] => 4131 [56] => 4130 [57] => 4129 [58] => 4128 [59] => 4058 [60] => 4054 [61] => 4051 [62] => 4050 [63] => 4047 [64] => 4046 [65] => 4045 [66] => 4043 [67] => 4042 [68] => 4041 [69] => 4040 [70] => 4038 [71] => 4036 [72] => 4035 [73] => 4032 [74] => 4029 [75] => 4028 [76] => 4024 [77] => 4022 [78] => 4021 [79] => 4020 [80] => 4017 [81] => 4016 [82] => 4014 [83] => 4013 [84] => 4012 [85] => 4011 [86] => 4009 [87] => 4007 [88] => 4006 [89] => 4004 [90] => 4003 [91] => 4002 [92] => 4001 [93] => 3997 [94] => 3869 [95] => 3886 [96] => 3884 [97] => 3883 [98] => 3882 [99] => 3881 [100] => 3880 [101] => 3878 [102] => 3877 [103] => 3876 [104] => 3875 [105] => 3874 [106] => 3873 [107] => 3870 [108] => 3863 [109] => 3861 [110] => 3860 [111] => 3859 [112] => 3858 [113] => 3857 [114] => 3856 [115] => 3855 [116] => 3854 [117] => 3852 [118] => 3851 [119] => 3849 [120] => 3848 [121] => 3847 [122] => 3846 [123] => 3845 [124] => 3819 [125] => 3812 [126] => 3810 [127] => 3809 [128] => 3808 [129] => 3807 [130] => 3806 [131] => 3805 [132] => 3804 [133] => 3803 [134] => 3802 [135] => 3801 [136] => 3800 [137] => 3799 [138] => 3798 [139] => 3797 [140] => 3796 [141] => 3792 [142] => 3791 [143] => 3789 [144] => 3788 [145] => 3786 [146] => 3785 [147] => 3784 [148] => 3783 [149] => 3782 [150] => 3781 [151] => 3778 [152] => 3769 [153] => 3768 [154] => 3765 [155] => 3764 [156] => 3758 [157] => 3741 [158] => 3696 [159] => 3495 [160] => 3493 [161] => 3436 [162] => 3434 [163] => 3433 [164] => 3431 [165] => 3430 [166] => 3428 [167] => 3427 [168] => 3426 [169] => 3424 [170] => 3422 [171] => 3421 [172] => 3420 [173] => 3372 [174] => 3370 [175] => 3368 [176] => 3366 [177] => 3364 [178] => 3361 [179] => 3360 [180] => 3356 [181] => 3354 [182] => 3352 [183] => 3221 [184] => 3220 [185] => 3219 [186] => 3218 [187] => 3217 [188] => 3216 [189] => 3215 [190] => 3127 [191] => 3126 [192] => 3125 [193] => 3124 [194] => 3123 [195] => 3122 [196] => 3121 [197] => 3120 [198] => 3119 [199] => 2956 [200] => 2961 [201] => 2965 [202] => 2947 [203] => 2960 [204] => 2964 [205] => 2958 [206] => 2949 [207] => 2957 [208] => 2962 [209] => 2945 [210] => 2909 [211] => 2908 [212] => 2907 [213] => 2893 [214] => 2892 [215] => 2890 [216] => 2889 [217] => 2885 [218] => 2824 [219] => 2823 [220] => 2822 [221] => 2820 [222] => 2744 [223] => 2749 [224] => 2748 [225] => 2743 [226] => 2742 [227] => 2741 [228] => 2739 [229] => 2737 [230] => 2736 [231] => 2734 [232] => 2543 [233] => 2540 [234] => 2541 [235] => 2542 [236] => 2544 [237] => 2545 [238] => 2547 [239] => 2549 [240] => 2553 [241] => 2457 [242] => 2461 [243] => 2462 [244] => 2463 [245] => 2464 [246] => 2465 [247] => 2466 [248] => 2467 [249] => 2470 [250] => 2473 [251] => 2474 [252] => 2475 [253] => 2476 [254] => 2477 [255] => 2479 [256] => 2481 [257] => 2482 [258] => 2471 [259] => 2454 [260] => 2452 [261] => 2450 [262] => 2449 [263] => 2448 [264] => 2444 [265] => 2443 [266] => 2442 [267] => 2441 [268] => 2426 [269] => 2424 [270] => 4808 [271] => 4807 [272] => 4806 [273] => 4805 [274] => 4804 [275] => 4802 [276] => 4801 [277] => 4800 [278] => 4798 [279] => 4797 [280] => 4796 [281] => 4661 [282] => 4147 [283] => 4601 [284] => 4148 [285] => 4223 [286] => 4222 [287] => 4221 [288] => 4220 [289] => 4219 [290] => 4218 [291] => 4217 [292] => 4216 [293] => 4215 [294] => 4214 [295] => 4213 [296] => 4212 [297] => 4210 [298] => 4209 [299] => 4205 [300] => 4204 [301] => 4201 [302] => 4200 [303] => 4161 [304] => 4159 [305] => 4158 [306] => 4157 [307] => 4156 [308] => 4155 [309] => 4154 [310] => 4153 [311] => 4152 [312] => 4151 [313] => 4150 [314] => 4149 [315] => 4146 [316] => 4141 [317] => 4140 [318] => 4139 [319] => 4138 [320] => 4137 [321] => 4136 [322] => 4135 [323] => 4134 [324] => 4133 [325] => 4131 [326] => 4130 [327] => 4129 [328] => 4128 [329] => 4058 [330] => 4054 [331] => 4051 [332] => 4050 [333] => 4047 [334] => 4046 [335] => 4045 [336] => 4043 [337] => 4042 [338] => 4041 [339] => 4040 [340] => 4038 [341] => 4036 [342] => 4035 [343] => 4032 [344] => 4029 [345] => 4028 [346] => 4024 [347] => 4022 [348] => 4021 [349] => 4020 [350] => 4017 [351] => 4016 [352] => 4014 [353] => 4013 [354] => 4012 [355] => 4011 [356] => 4009 [357] => 4007 [358] => 4006 [359] => 4004 [360] => 4003 [361] => 4002 [362] => 4001 [363] => 3997 [364] => 3869 [365] => 3886 [366] => 3884 [367] => 3883 [368] => 3882 [369] => 3881 [370] => 3880 [371] => 3878 [372] => 3877 [373] => 3876 [374] => 3875 [375] => 3874 [376] => 3873 [377] => 3870 [378] => 3863 [379] => 3861 [380] => 3860 [381] => 3859 [382] => 3858 [383] => 3857 [384] => 3856 [385] => 3855 [386] => 3854 [387] => 3852 [388] => 3851 [389] => 3849 [390] => 3848 [391] => 3847 [392] => 3846 [393] => 3845 [394] => 3819 [395] => 3812 [396] => 3810 [397] => 3809 [398] => 3808 [399] => 3807 [400] => 3806 [401] => 3805 [402] => 3804 [403] => 3803 [404] => 3802 [405] => 3801 [406] => 3800 [407] => 3799 [408] => 3798 [409] => 3797 [410] => 3796 [411] => 3792 [412] => 3791 [413] => 3789 [414] => 3788 [415] => 3786 [416] => 3785 [417] => 3784 [418] => 3783 [419] => 3782 [420] => 3781 [421] => 3778 [422] => 3769 [423] => 3768 [424] => 3765 [425] => 3764 [426] => 3758 [427] => 3741 [428] => 3696 [429] => 3495 [430] => 3493 [431] => 3436 [432] => 3434 [433] => 3433 [434] => 3431 [435] => 3430 [436] => 3428 [437] => 3427 [438] => 3426 [439] => 3424 [440] => 3422 [441] => 3421 [442] => 3420 [443] => 3372 [444] => 3370 [445] => 3368 [446] => 3366 [447] => 3364 [448] => 3361 [449] => 3360 [450] => 3356 [451] => 3354 [452] => 3352 [453] => 3221 [454] => 3220 [455] => 3219 [456] => 3218 [457] => 3217 [458] => 3216 [459] => 3215 [460] => 3127 [461] => 3126 [462] => 3125 [463] => 3124 [464] => 3123 [465] => 3122 [466] => 3121 [467] => 3120 [468] => 3119 [469] => 2956 [470] => 2961 [471] => 2965 [472] => 2947 [473] => 2960 [474] => 2964 [475] => 2958 [476] => 2949 [477] => 2957 [478] => 2962 [479] => 2945 [480] => 2909 [481] => 2908 [482] => 2907 [483] => 2893 [484] => 2892 [485] => 2890 [486] => 2889 [487] => 2885 [488] => 2824 [489] => 2823 [490] => 2822 [491] => 2820 [492] => 2744 [493] => 2749 [494] => 2748 [495] => 2743 [496] => 2742 [497] => 2741 [498] => 2739 [499] => 2737 [500] => 2736 [501] => 2734 [502] => 2543 [503] => 2540 [504] => 2541 [505] => 2542 [506] => 2544 [507] => 2545 [508] => 2547 [509] => 2549 [510] => 2553 [511] => 2457 [512] => 2461 [513] => 2462 [514] => 2463 [515] => 2464 [516] => 2465 [517] => 2466 [518] => 2467 [519] => 2470 [520] => 2473 [521] => 2474 [522] => 2475 [523] => 2476 [524] => 2477 [525] => 2479 [526] => 2481 [527] => 2482 [528] => 2471 [529] => 2454 [530] => 2452 [531] => 2450 [532] => 2449 [533] => 2448 [534] => 2444 [535] => 2443 [536] => 2442 [537] => 2441 [538] => 2426 [539] => 2424 [540] => 3909 [541] => 3908 [542] => 3906 [543] => 3904 [544] => 3903 [545] => 3901 [546] => 3900 [547] => 3899 [548] => 3898 [549] => 3897 [550] => 3896 [551] => 3895 [552] => 3892 [553] => 3891 [554] => 3890 [555] => 3418 [556] => 3417 [557] => 3416 [558] => 3415 [559] => 3414 [560] => 3413 [561] => 3412 [562] => 3411 [563] => 3410 [564] => 3409 [565] => 3406 [566] => 3304 [567] => 2873 [568] => 2872 [569] => 2870 [570] => 2869 [571] => 2867 ) ) [text_agreement_args] => Array ( [post_type] => agreement [posts_per_page] => -1 [s] => covid 19 ) [text_provision_args] => Array ( [post_type] => provision_document [posts_per_page] => -1 [s] => covid 19 ) [agreement_ids] => Array ( ) [agreement_q_rslts] => [provision_q_rslts] => [text_agreement_q_rslts] => WP_Query Object ( [query] => Array ( [post_type] => agreement [posts_per_page] => -1 [s] => covid 19 ) [query_vars] => Array ( [post_type] => agreement [posts_per_page] => -1 [s] => covid 19 [error] => [m] => [p] => 0 [post_parent] => [subpost] => [subpost_id] => [attachment] => [attachment_id] => 0 [name] => [pagename] => [page_id] => 0 [second] => [minute] => [hour] => [day] => 0 [monthnum] => 0 [year] => 0 [w] => 0 [category_name] => [tag] => [cat] => [tag_id] => [author] => [author_name] => [feed] => [tb] => [paged] => 0 [meta_key] => [meta_value] => [preview] => [sentence] => [title] => [fields] => [menu_order] => [embed] => [category__in] => Array ( ) [category__not_in] => Array ( ) [category__and] => Array ( ) [post__in] => Array ( ) [post__not_in] => Array ( ) [post_name__in] => Array ( ) [tag__in] => Array ( ) [tag__not_in] => Array ( ) [tag__and] => Array ( ) [tag_slug__in] => Array ( ) [tag_slug__and] => Array ( ) [post_parent__in] => Array ( ) [post_parent__not_in] => Array ( ) [author__in] => Array ( ) [author__not_in] => Array ( ) [orderby] => title [order] => ASC [suppress_filters] => [ignore_sticky_posts] => [cache_results] => 1 [update_post_term_cache] => 1 [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [nopaging] => 1 [comments_per_page] => 50 [no_found_rows] => [search_terms_count] => 2 [search_terms] => Array ( [0] => covid [1] => 19 ) [search_orderby_title] => Array ( [0] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' [1] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' ) ) [tax_query] => WP_Tax_Query Object ( [queries] => Array ( ) [relation] => AND [table_aliases:protected] => Array ( ) [queried_terms] => Array ( ) [primary_table] => wpry_posts [primary_id_column] => ID ) [meta_query] => WP_Meta_Query Object ( [queries] => Array ( ) [relation] => [meta_table] => [meta_id_column] => [primary_table] => [primary_id_column] => [table_aliases:protected] => Array ( ) [clauses:protected] => Array ( ) [has_or_relation:protected] => ) [date_query] => [request] => SELECT DISTINCT wpry_posts.* FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) ) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled'))) ORDER BY wpry_posts.post_title ASC [posts] => Array ( [0] => WP_Post Object ( [ID] => 2438 [post_author] => 5 [post_date] => 2021-01-19 06:43:39 [post_date_gmt] => 2021-01-19 06:43:39 [post_content] => [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2 [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:05:25 [post_modified_gmt] => 2021-09-15 12:05:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2438 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4207 [post_author] => 5 [post_date] => 2022-03-02 11:38:41 [post_date_gmt] => 2022-03-02 11:38:41 [post_content] => [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement [to_ping] => [pinged] => [post_modified] => 2022-03-02 11:38:51 [post_modified_gmt] => 2022-03-02 11:38:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=4207 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4126 [post_author] => 5 [post_date] => 2022-01-28 13:33:11 [post_date_gmt] => 2022-01-28 13:33:11 [post_content] => [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-28 13:33:11 [post_modified_gmt] => 2022-01-28 13:33:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=4126 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2882 [post_author] => 6 [post_date] => 2021-05-14 14:03:29 [post_date_gmt] => 2021-05-14 14:03:29 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 11:58:31 [post_modified_gmt] => 2021-09-15 11:58:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2882 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 4794 [post_author] => 5 [post_date] => 2022-05-23 13:54:39 [post_date_gmt] => 2022-05-23 13:54:39 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-05-23 13:54:39 [post_modified_gmt] => 2022-05-23 13:54:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=4794 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 3817 [post_author] => 6 [post_date] => 2021-09-15 10:46:18 [post_date_gmt] => 2021-09-15 10:46:18 [post_content] => [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-and-gsk-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-13 13:58:20 [post_modified_gmt] => 2021-12-13 13:58:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3817 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [6] => WP_Post Object ( [ID] => 3117 [post_author] => 6 [post_date] => 2021-06-03 14:15:12 [post_date_gmt] => 2021-06-03 14:15:12 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:00:38 [post_modified_gmt] => 2021-09-15 12:00:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3117 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [7] => WP_Post Object ( [ID] => 2538 [post_author] => 5 [post_date] => 2021-03-12 13:41:11 [post_date_gmt] => 2021-03-12 13:41:11 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => advance-purchase-agreement-for-the-production-purchase-and-supply-of-a-covid-19-vaccine-in-the-european-union-with-astrazeneca [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:05:41 [post_modified_gmt] => 2021-09-15 12:05:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2538 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [8] => WP_Post Object ( [ID] => 2468 [post_author] => 5 [post_date] => 2021-02-25 15:15:43 [post_date_gmt] => 2021-02-25 15:15:43 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => advance-purchase-agreement-for-the-development-production-advance-purchase-and-supply-of-a-covid-19-vaccine-for-eu-member-states-with-curevac [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:00:56 [post_modified_gmt] => 2021-09-15 12:00:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2468 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [9] => WP_Post Object ( [ID] => 3419 [post_author] => 6 [post_date] => 2021-07-01 01:45:34 [post_date_gmt] => 2021-07-01 01:45:34 [post_content] => [post_title] => Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement [to_ping] => [pinged] => [post_modified] => 2021-11-10 18:22:02 [post_modified_gmt] => 2021-11-10 18:22:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3419 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [10] => WP_Post Object ( [ID] => 3843 [post_author] => 5 [post_date] => 2021-11-05 10:54:08 [post_date_gmt] => 2021-11-05 10:54:08 [post_content] => [post_title] => Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement [to_ping] => [pinged] => [post_modified] => 2021-11-05 10:54:08 [post_modified_gmt] => 2021-11-05 10:54:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3843 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [11] => WP_Post Object ( [ID] => 4142 [post_author] => 5 [post_date] => 2022-02-01 18:56:28 [post_date_gmt] => 2022-02-01 18:56:28 [post_content] => [post_title] => Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-02-02 07:30:00 [post_modified_gmt] => 2022-02-02 07:30:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=4142 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [12] => WP_Post Object ( [ID] => 3867 [post_author] => 5 [post_date] => 2021-11-18 12:26:40 [post_date_gmt] => 2021-11-18 12:26:40 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement [to_ping] => [pinged] => [post_modified] => 2021-11-18 12:26:40 [post_modified_gmt] => 2021-11-18 12:26:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3867 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [13] => WP_Post Object ( [ID] => 3348 [post_author] => 5 [post_date] => 2021-06-30 13:13:40 [post_date_gmt] => 2021-06-30 13:13:40 [post_content] => [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:18:24 [post_modified_gmt] => 2021-09-15 12:18:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3348 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [14] => WP_Post Object ( [ID] => 3794 [post_author] => 5 [post_date] => 2021-09-10 08:02:49 [post_date_gmt] => 2021-09-10 08:02:49 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:20:53 [post_modified_gmt] => 2021-09-15 12:20:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3794 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [15] => WP_Post Object ( [ID] => 4026 [post_author] => 5 [post_date] => 2021-12-21 11:36:17 [post_date_gmt] => 2021-12-21 11:36:17 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-21 11:36:17 [post_modified_gmt] => 2021-12-21 11:36:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=4026 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [16] => WP_Post Object ( [ID] => 3213 [post_author] => 6 [post_date] => 2021-06-28 12:04:36 [post_date_gmt] => 2021-06-28 12:04:36 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:03:12 [post_modified_gmt] => 2021-09-15 12:03:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3213 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [17] => WP_Post Object ( [ID] => 2420 [post_author] => 5 [post_date] => 2020-12-14 14:59:07 [post_date_gmt] => 2020-12-14 14:59:07 [post_content] => [post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:03:29 [post_modified_gmt] => 2021-09-15 12:03:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2420 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [18] => WP_Post Object ( [ID] => 2943 [post_author] => 6 [post_date] => 2021-05-28 13:48:32 [post_date_gmt] => 2021-05-28 13:48:32 [post_content] => [post_title] => UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222 [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:12:31 [post_modified_gmt] => 2021-09-15 12:12:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2943 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [19] => WP_Post Object ( [ID] => 2817 [post_author] => 5 [post_date] => 2021-04-16 11:58:45 [post_date_gmt] => 2021-04-16 11:58:45 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2 [to_ping] => [pinged] => [post_modified] => 2022-01-12 15:16:34 [post_modified_gmt] => 2022-01-12 15:16:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2817 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [20] => WP_Post Object ( [ID] => 3776 [post_author] => 5 [post_date] => 2021-09-09 11:24:04 [post_date_gmt] => 2021-09-09 11:24:04 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:12:55 [post_modified_gmt] => 2021-09-15 12:12:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=3776 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [21] => WP_Post Object ( [ID] => 2446 [post_author] => 5 [post_date] => 2021-01-19 09:42:42 [post_date_gmt] => 2021-01-19 09:42:42 [post_content] => [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => award-contract-no-w911qy20c0100-by-and-between-modernatx-inc-and-the-department-of-defense [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:03:43 [post_modified_gmt] => 2021-09-15 12:03:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2446 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [22] => WP_Post Object ( [ID] => 2732 [post_author] => 5 [post_date] => 2021-03-23 15:54:07 [post_date_gmt] => 2021-03-23 15:54:07 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:18:39 [post_modified_gmt] => 2021-09-15 12:18:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2732 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [23] => WP_Post Object ( [ID] => 2455 [post_author] => 5 [post_date] => 2021-02-25 15:19:51 [post_date_gmt] => 2021-02-25 15:19:51 [post_content] => [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:13:19 [post_modified_gmt] => 2021-09-15 12:13:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2455 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 24 [current_post] => -1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 2438 [post_author] => 5 [post_date] => 2021-01-19 06:43:39 [post_date_gmt] => 2021-01-19 06:43:39 [post_content] => [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2 [to_ping] => [pinged] => [post_modified] => 2021-09-15 12:05:25 [post_modified_gmt] => 2021-09-15 12:05:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=agreement&p=2438 [menu_order] => 0 [post_type] => agreement [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 24 [max_num_pages] => 0 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => 1 [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => 1 [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => 1 [query_vars_hash:WP_Query:private] => 1fc2d19f378284cf7496bf5ba612c2e6 [query_vars_changed:WP_Query:private] => 1 [thumbnails_cached] => [stopwords:WP_Query:private] => Array ( [0] => about [1] => an [2] => are [3] => as [4] => at [5] => be [6] => by [7] => com [8] => for [9] => from [10] => how [11] => in [12] => is [13] => it [14] => of [15] => on [16] => or [17] => that [18] => the [19] => this [20] => to [21] => was [22] => what [23] => when [24] => where [25] => who [26] => will [27] => with [28] => www ) [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) ) [text_provision_q_rslts] => WP_Query Object ( [query] => Array ( [post_type] => provision_document [posts_per_page] => -1 [s] => covid 19 ) [query_vars] => Array ( [post_type] => provision_document [posts_per_page] => -1 [s] => covid 19 [error] => [m] => [p] => 0 [post_parent] => [subpost] => [subpost_id] => [attachment] => [attachment_id] => 0 [name] => [pagename] => [page_id] => 0 [second] => [minute] => [hour] => [day] => 0 [monthnum] => 0 [year] => 0 [w] => 0 [category_name] => [tag] => [cat] => [tag_id] => [author] => [author_name] => [feed] => [tb] => [paged] => 0 [meta_key] => [meta_value] => [preview] => [sentence] => [title] => [fields] => [menu_order] => [embed] => [category__in] => Array ( ) [category__not_in] => Array ( ) [category__and] => Array ( ) [post__in] => Array ( ) [post__not_in] => Array ( ) [post_name__in] => Array ( ) [tag__in] => Array ( ) [tag__not_in] => Array ( ) [tag__and] => Array ( ) [tag_slug__in] => Array ( ) [tag_slug__and] => Array ( ) [post_parent__in] => Array ( ) [post_parent__not_in] => Array ( ) [author__in] => Array ( ) [author__not_in] => Array ( ) [suppress_filters] => [ignore_sticky_posts] => [cache_results] => 1 [update_post_term_cache] => 1 [lazy_load_term_meta] => 1 [update_post_meta_cache] => 1 [nopaging] => 1 [comments_per_page] => 50 [no_found_rows] => [search_terms_count] => 2 [search_terms] => Array ( [0] => covid [1] => 19 ) [search_orderby_title] => Array ( [0] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' [1] => wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' ) [order] => DESC ) [tax_query] => WP_Tax_Query Object ( [queries] => Array ( ) [relation] => AND [table_aliases:protected] => Array ( ) [queried_terms] => Array ( ) [primary_table] => wpry_posts [primary_id_column] => ID ) [meta_query] => WP_Meta_Query Object ( [queries] => Array ( ) [relation] => [meta_table] => [meta_id_column] => [primary_table] => [primary_id_column] => [table_aliases:protected] => Array ( ) [clauses:protected] => Array ( ) [has_or_relation:protected] => ) [date_query] => [request] => SELECT DISTINCT wpry_posts.* FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) ) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled'))) ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid 19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 1 WHEN wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' AND wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 2 WHEN wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' OR wpry_posts.post_title LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 3 WHEN wpry_posts.post_excerpt LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid 19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 4 WHEN wpry_posts.post_content LIKE '{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}covid 19{9e7594c18e5c87d099432b2bfa4d575eb796281f423cdce0807110c97e3a86fb}' THEN 5 ELSE 6 END), wpry_posts.post_date DESC [posts] => Array ( [0] => WP_Post Object ( [ID] => 4808 [post_author] => 5 [post_date] => 2022-05-24 09:09:54 [post_date_gmt] => 2022-05-24 09:09:54 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-05-24 09:09:54 [post_modified_gmt] => 2022-05-24 09:09:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4807 [post_author] => 5 [post_date] => 2022-05-24 09:02:55 [post_date_gmt] => 2022-05-24 09:02:55 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-05-24 09:02:55 [post_modified_gmt] => 2022-05-24 09:02:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4806 [post_author] => 5 [post_date] => 2022-05-24 08:59:08 [post_date_gmt] => 2022-05-24 08:59:08 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:59:08 [post_modified_gmt] => 2022-05-24 08:59:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4805 [post_author] => 5 [post_date] => 2022-05-24 08:53:12 [post_date_gmt] => 2022-05-24 08:53:12 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:59:42 [post_modified_gmt] => 2022-05-24 08:59:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 4804 [post_author] => 5 [post_date] => 2022-05-24 08:40:15 [post_date_gmt] => 2022-05-24 08:40:15 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:53:51 [post_modified_gmt] => 2022-05-24 08:53:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 4802 [post_author] => 5 [post_date] => 2022-05-24 08:24:23 [post_date_gmt] => 2022-05-24 08:24:23 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:24:23 [post_modified_gmt] => 2022-05-24 08:24:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [6] => WP_Post Object ( [ID] => 4801 [post_author] => 5 [post_date] => 2022-05-24 08:19:21 [post_date_gmt] => 2022-05-24 08:19:21 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:19:21 [post_modified_gmt] => 2022-05-24 08:19:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4801 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [7] => WP_Post Object ( [ID] => 4800 [post_author] => 5 [post_date] => 2022-05-24 08:07:39 [post_date_gmt] => 2022-05-24 08:07:39 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:08:30 [post_modified_gmt] => 2022-05-24 08:08:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [8] => WP_Post Object ( [ID] => 4798 [post_author] => 5 [post_date] => 2022-05-23 14:11:13 [post_date_gmt] => 2022-05-23 14:11:13 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-05-23 14:12:44 [post_modified_gmt] => 2022-05-23 14:12:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [9] => WP_Post Object ( [ID] => 4797 [post_author] => 5 [post_date] => 2022-05-23 13:54:57 [post_date_gmt] => 2022-05-23 13:54:57 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-05-23 13:54:57 [post_modified_gmt] => 2022-05-23 13:54:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4797 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [10] => WP_Post Object ( [ID] => 4796 [post_author] => 5 [post_date] => 2022-05-23 13:54:05 [post_date_gmt] => 2022-05-23 13:54:05 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-05-23 14:21:34 [post_modified_gmt] => 2022-05-23 14:21:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4796 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [11] => WP_Post Object ( [ID] => 4661 [post_author] => 5 [post_date] => 2022-04-20 08:13:06 [post_date_gmt] => 2022-04-20 08:13:06 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:13:06 [post_modified_gmt] => 2022-04-20 08:13:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4661 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [12] => WP_Post Object ( [ID] => 4147 [post_author] => 5 [post_date] => 2022-04-18 12:53:51 [post_date_gmt] => 2022-04-18 12:53:51 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:22:54 [post_modified_gmt] => 2022-04-18 13:22:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4147 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [13] => WP_Post Object ( [ID] => 4601 [post_author] => 5 [post_date] => 2022-04-18 10:40:48 [post_date_gmt] => 2022-04-18 10:40:48 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:44:46 [post_modified_gmt] => 2022-04-18 10:44:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4601 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [14] => WP_Post Object ( [ID] => 4148 [post_author] => 5 [post_date] => 2022-04-12 08:59:45 [post_date_gmt] => 2022-04-12 08:59:45 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:55:19 [post_modified_gmt] => 2022-04-18 13:55:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4148 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [15] => WP_Post Object ( [ID] => 4223 [post_author] => 5 [post_date] => 2022-03-04 09:43:58 [post_date_gmt] => 2022-03-04 09:43:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-03-04 09:43:58 [post_modified_gmt] => 2022-03-04 09:43:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4223 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [16] => WP_Post Object ( [ID] => 4222 [post_author] => 5 [post_date] => 2022-03-04 09:14:41 [post_date_gmt] => 2022-03-04 09:14:41 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:51:38 [post_modified_gmt] => 2022-03-08 13:51:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4222 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [17] => WP_Post Object ( [ID] => 4221 [post_author] => 5 [post_date] => 2022-03-04 09:05:29 [post_date_gmt] => 2022-03-04 09:05:29 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-04 09:05:29 [post_modified_gmt] => 2022-03-04 09:05:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [18] => WP_Post Object ( [ID] => 4220 [post_author] => 5 [post_date] => 2022-03-04 08:47:04 [post_date_gmt] => 2022-03-04 08:47:04 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-03-04 08:47:04 [post_modified_gmt] => 2022-03-04 08:47:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4220 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [19] => WP_Post Object ( [ID] => 4219 [post_author] => 5 [post_date] => 2022-03-04 08:02:15 [post_date_gmt] => 2022-03-04 08:02:15 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-03-04 08:47:42 [post_modified_gmt] => 2022-03-04 08:47:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4219 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [20] => WP_Post Object ( [ID] => 4218 [post_author] => 5 [post_date] => 2022-03-03 14:17:53 [post_date_gmt] => 2022-03-03 14:17:53 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-03-03 14:17:53 [post_modified_gmt] => 2022-03-03 14:17:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4218 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [21] => WP_Post Object ( [ID] => 4217 [post_author] => 5 [post_date] => 2022-03-03 13:59:58 [post_date_gmt] => 2022-03-03 13:59:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-03 14:11:50 [post_modified_gmt] => 2022-03-03 14:11:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4217 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [22] => WP_Post Object ( [ID] => 4216 [post_author] => 5 [post_date] => 2022-03-03 13:45:21 [post_date_gmt] => 2022-03-03 13:45:21 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-03 13:45:46 [post_modified_gmt] => 2022-03-03 13:45:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4216 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [23] => WP_Post Object ( [ID] => 4215 [post_author] => 5 [post_date] => 2022-03-03 13:31:56 [post_date_gmt] => 2022-03-03 13:31:56 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-03-03 13:42:58 [post_modified_gmt] => 2022-03-03 13:42:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4215 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [24] => WP_Post Object ( [ID] => 4214 [post_author] => 5 [post_date] => 2022-03-03 12:54:33 [post_date_gmt] => 2022-03-03 12:54:33 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-03-21 13:17:07 [post_modified_gmt] => 2022-03-21 13:17:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4214 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [25] => WP_Post Object ( [ID] => 4213 [post_author] => 5 [post_date] => 2022-03-03 10:54:01 [post_date_gmt] => 2022-03-03 10:54:01 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-03-03 10:58:00 [post_modified_gmt] => 2022-03-03 10:58:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4213 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [26] => WP_Post Object ( [ID] => 4212 [post_author] => 5 [post_date] => 2022-03-02 14:54:16 [post_date_gmt] => 2022-03-02 14:54:16 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:51:03 [post_modified_gmt] => 2022-03-08 13:51:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4212 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [27] => WP_Post Object ( [ID] => 4210 [post_author] => 5 [post_date] => 2022-03-02 13:14:31 [post_date_gmt] => 2022-03-02 13:14:31 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-02 13:14:31 [post_modified_gmt] => 2022-03-02 13:14:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4210 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [28] => WP_Post Object ( [ID] => 4209 [post_author] => 5 [post_date] => 2022-03-02 12:07:13 [post_date_gmt] => 2022-03-02 12:07:13 [post_content] => [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement [to_ping] => [pinged] => [post_modified] => 2022-03-04 10:05:30 [post_modified_gmt] => 2022-03-04 10:05:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4209 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [29] => WP_Post Object ( [ID] => 4205 [post_author] => 5 [post_date] => 2022-02-28 15:24:19 [post_date_gmt] => 2022-02-28 15:24:19 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-02-28 15:24:19 [post_modified_gmt] => 2022-02-28 15:24:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4205 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [30] => WP_Post Object ( [ID] => 4204 [post_author] => 5 [post_date] => 2022-02-28 14:53:11 [post_date_gmt] => 2022-02-28 14:53:11 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-02-28 14:53:11 [post_modified_gmt] => 2022-02-28 14:53:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4204 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [31] => WP_Post Object ( [ID] => 4201 [post_author] => 5 [post_date] => 2022-02-28 13:33:22 [post_date_gmt] => 2022-02-28 13:33:22 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-02-28 14:46:09 [post_modified_gmt] => 2022-02-28 14:46:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4201 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [32] => WP_Post Object ( [ID] => 4200 [post_author] => 5 [post_date] => 2022-02-28 13:13:29 [post_date_gmt] => 2022-02-28 13:13:29 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:54:57 [post_modified_gmt] => 2022-03-08 13:54:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4200 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [33] => WP_Post Object ( [ID] => 4161 [post_author] => 5 [post_date] => 2022-02-02 13:48:58 [post_date_gmt] => 2022-02-02 13:48:58 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:17:00 [post_modified_gmt] => 2022-04-18 13:17:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4161 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [34] => WP_Post Object ( [ID] => 4159 [post_author] => 5 [post_date] => 2022-02-02 13:10:48 [post_date_gmt] => 2022-02-02 13:10:48 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:16:05 [post_modified_gmt] => 2022-04-18 13:16:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4159 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [35] => WP_Post Object ( [ID] => 4158 [post_author] => 5 [post_date] => 2022-02-02 13:00:08 [post_date_gmt] => 2022-02-02 13:00:08 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:15:30 [post_modified_gmt] => 2022-04-18 13:15:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4158 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [36] => WP_Post Object ( [ID] => 4157 [post_author] => 5 [post_date] => 2022-02-02 12:54:56 [post_date_gmt] => 2022-02-02 12:54:56 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:13:37 [post_modified_gmt] => 2022-04-18 13:13:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [37] => WP_Post Object ( [ID] => 4156 [post_author] => 5 [post_date] => 2022-02-02 12:36:42 [post_date_gmt] => 2022-02-02 12:36:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:12:51 [post_modified_gmt] => 2022-04-18 13:12:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4156 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [38] => WP_Post Object ( [ID] => 4155 [post_author] => 5 [post_date] => 2022-02-02 12:19:16 [post_date_gmt] => 2022-02-02 12:19:16 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:12:26 [post_modified_gmt] => 2022-04-18 13:12:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4155 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [39] => WP_Post Object ( [ID] => 4154 [post_author] => 5 [post_date] => 2022-02-02 12:13:41 [post_date_gmt] => 2022-02-02 12:13:41 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-02-02 12:13:41 [post_modified_gmt] => 2022-02-02 12:13:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4154 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [40] => WP_Post Object ( [ID] => 4153 [post_author] => 5 [post_date] => 2022-02-02 12:10:13 [post_date_gmt] => 2022-02-02 12:10:13 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:02:30 [post_modified_gmt] => 2022-04-18 13:02:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4153 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [41] => WP_Post Object ( [ID] => 4152 [post_author] => 5 [post_date] => 2022-02-02 11:51:54 [post_date_gmt] => 2022-02-02 11:51:54 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:02:06 [post_modified_gmt] => 2022-04-18 13:02:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [42] => WP_Post Object ( [ID] => 4151 [post_author] => 5 [post_date] => 2022-02-02 11:39:24 [post_date_gmt] => 2022-02-02 11:39:24 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:01:35 [post_modified_gmt] => 2022-04-18 13:01:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [43] => WP_Post Object ( [ID] => 4150 [post_author] => 5 [post_date] => 2022-02-02 10:24:30 [post_date_gmt] => 2022-02-02 10:24:30 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:01:03 [post_modified_gmt] => 2022-04-18 13:01:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [44] => WP_Post Object ( [ID] => 4149 [post_author] => 5 [post_date] => 2022-02-02 10:15:42 [post_date_gmt] => 2022-02-02 10:15:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:00:34 [post_modified_gmt] => 2022-04-18 13:00:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4149 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [45] => WP_Post Object ( [ID] => 4146 [post_author] => 5 [post_date] => 2022-02-02 07:28:42 [post_date_gmt] => 2022-02-02 07:28:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-18 12:57:05 [post_modified_gmt] => 2022-04-18 12:57:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4146 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [46] => WP_Post Object ( [ID] => 4141 [post_author] => 5 [post_date] => 2022-01-31 14:31:23 [post_date_gmt] => 2022-01-31 14:31:23 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-01-31 14:33:23 [post_modified_gmt] => 2022-01-31 14:33:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4141 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [47] => WP_Post Object ( [ID] => 4140 [post_author] => 5 [post_date] => 2022-01-31 14:22:03 [post_date_gmt] => 2022-01-31 14:22:03 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:11:05 [post_modified_gmt] => 2022-03-09 13:11:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4140 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [48] => WP_Post Object ( [ID] => 4139 [post_author] => 5 [post_date] => 2022-01-31 14:18:32 [post_date_gmt] => 2022-01-31 14:18:32 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-02-11 11:35:27 [post_modified_gmt] => 2022-02-11 11:35:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4139 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [49] => WP_Post Object ( [ID] => 4138 [post_author] => 5 [post_date] => 2022-01-31 14:09:33 [post_date_gmt] => 2022-01-31 14:09:33 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-31 14:09:33 [post_modified_gmt] => 2022-01-31 14:09:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4138 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [50] => WP_Post Object ( [ID] => 4137 [post_author] => 5 [post_date] => 2022-01-31 13:53:37 [post_date_gmt] => 2022-01-31 13:53:37 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-31 13:54:45 [post_modified_gmt] => 2022-01-31 13:54:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4137 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [51] => WP_Post Object ( [ID] => 4136 [post_author] => 5 [post_date] => 2022-01-31 13:42:47 [post_date_gmt] => 2022-01-31 13:42:47 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-01-31 13:42:47 [post_modified_gmt] => 2022-01-31 13:42:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4136 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [52] => WP_Post Object ( [ID] => 4135 [post_author] => 5 [post_date] => 2022-01-31 13:25:08 [post_date_gmt] => 2022-01-31 13:25:08 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-31 13:25:08 [post_modified_gmt] => 2022-01-31 13:25:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4135 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [53] => WP_Post Object ( [ID] => 4134 [post_author] => 5 [post_date] => 2022-01-31 12:56:28 [post_date_gmt] => 2022-01-31 12:56:28 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-01-31 12:56:28 [post_modified_gmt] => 2022-01-31 12:56:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4134 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [54] => WP_Post Object ( [ID] => 4133 [post_author] => 5 [post_date] => 2022-01-31 12:22:56 [post_date_gmt] => 2022-01-31 12:22:56 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-01-31 12:24:36 [post_modified_gmt] => 2022-01-31 12:24:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4133 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [55] => WP_Post Object ( [ID] => 4131 [post_author] => 5 [post_date] => 2022-01-29 16:21:19 [post_date_gmt] => 2022-01-29 16:21:19 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-01-29 16:31:13 [post_modified_gmt] => 2022-01-29 16:31:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [56] => WP_Post Object ( [ID] => 4130 [post_author] => 5 [post_date] => 2022-01-29 15:34:50 [post_date_gmt] => 2022-01-29 15:34:50 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-29 15:49:57 [post_modified_gmt] => 2022-01-29 15:49:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [57] => WP_Post Object ( [ID] => 4129 [post_author] => 5 [post_date] => 2022-01-28 14:43:06 [post_date_gmt] => 2022-01-28 14:43:06 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-31 16:21:05 [post_modified_gmt] => 2022-03-31 16:21:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [58] => WP_Post Object ( [ID] => 4128 [post_author] => 5 [post_date] => 2022-01-28 13:38:44 [post_date_gmt] => 2022-01-28 13:38:44 [post_content] => [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-28 13:45:11 [post_modified_gmt] => 2022-01-28 13:45:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4128 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [59] => WP_Post Object ( [ID] => 4058 [post_author] => 5 [post_date] => 2022-01-04 14:25:52 [post_date_gmt] => 2022-01-04 14:25:52 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-04 14:25:52 [post_modified_gmt] => 2022-01-04 14:25:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4058 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [60] => WP_Post Object ( [ID] => 4054 [post_author] => 5 [post_date] => 2022-01-03 11:45:52 [post_date_gmt] => 2022-01-03 11:45:52 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20 [to_ping] => [pinged] => [post_modified] => 2022-01-03 11:46:09 [post_modified_gmt] => 2022-01-03 11:46:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4054 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [61] => WP_Post Object ( [ID] => 4051 [post_author] => 5 [post_date] => 2022-01-03 11:01:41 [post_date_gmt] => 2022-01-03 11:01:41 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-03-09 10:37:08 [post_modified_gmt] => 2022-03-09 10:37:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4051 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [62] => WP_Post Object ( [ID] => 4050 [post_author] => 5 [post_date] => 2022-01-03 10:49:32 [post_date_gmt] => 2022-01-03 10:49:32 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-01-03 10:56:55 [post_modified_gmt] => 2022-01-03 10:56:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4050 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [63] => WP_Post Object ( [ID] => 4047 [post_author] => 5 [post_date] => 2021-12-27 17:17:36 [post_date_gmt] => 2021-12-27 17:17:36 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-01-03 10:43:10 [post_modified_gmt] => 2022-01-03 10:43:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4047 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [64] => WP_Post Object ( [ID] => 4046 [post_author] => 5 [post_date] => 2021-12-27 17:10:47 [post_date_gmt] => 2021-12-27 17:10:47 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14 [to_ping] => [pinged] => [post_modified] => 2021-12-27 17:10:47 [post_modified_gmt] => 2021-12-27 17:10:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4046 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [65] => WP_Post Object ( [ID] => 4045 [post_author] => 5 [post_date] => 2021-12-27 17:07:25 [post_date_gmt] => 2021-12-27 17:07:25 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13 [to_ping] => [pinged] => [post_modified] => 2021-12-27 17:07:25 [post_modified_gmt] => 2021-12-27 17:07:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4045 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [66] => WP_Post Object ( [ID] => 4043 [post_author] => 5 [post_date] => 2021-12-27 16:47:54 [post_date_gmt] => 2021-12-27 16:47:54 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-12-27 16:47:54 [post_modified_gmt] => 2021-12-27 16:47:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4043 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [67] => WP_Post Object ( [ID] => 4042 [post_author] => 5 [post_date] => 2021-12-27 16:41:56 [post_date_gmt] => 2021-12-27 16:41:56 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-27 10:56:31 [post_modified_gmt] => 2022-01-27 10:56:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4042 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [68] => WP_Post Object ( [ID] => 4041 [post_author] => 5 [post_date] => 2021-12-27 16:28:21 [post_date_gmt] => 2021-12-27 16:28:21 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9 [to_ping] => [pinged] => [post_modified] => 2021-12-27 16:28:42 [post_modified_gmt] => 2021-12-27 16:28:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4041 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [69] => WP_Post Object ( [ID] => 4040 [post_author] => 5 [post_date] => 2021-12-27 15:24:04 [post_date_gmt] => 2021-12-27 15:24:04 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-14 12:58:21 [post_modified_gmt] => 2022-03-14 12:58:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4040 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [70] => WP_Post Object ( [ID] => 4038 [post_author] => 5 [post_date] => 2021-12-27 15:08:30 [post_date_gmt] => 2021-12-27 15:08:30 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-24 12:22:28 [post_modified_gmt] => 2022-01-24 12:22:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4038 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [71] => WP_Post Object ( [ID] => 4036 [post_author] => 5 [post_date] => 2021-12-26 17:01:45 [post_date_gmt] => 2021-12-26 17:01:45 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:22:53 [post_modified_gmt] => 2022-02-11 13:22:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4036 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [72] => WP_Post Object ( [ID] => 4035 [post_author] => 5 [post_date] => 2021-12-26 16:47:36 [post_date_gmt] => 2021-12-26 16:47:36 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-12-26 16:47:36 [post_modified_gmt] => 2021-12-26 16:47:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4035 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [73] => WP_Post Object ( [ID] => 4032 [post_author] => 5 [post_date] => 2021-12-26 16:32:27 [post_date_gmt] => 2021-12-26 16:32:27 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-22 14:37:29 [post_modified_gmt] => 2022-01-22 14:37:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4032 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [74] => WP_Post Object ( [ID] => 4029 [post_author] => 5 [post_date] => 2021-12-21 12:22:08 [post_date_gmt] => 2021-12-21 12:22:08 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-24 12:10:58 [post_modified_gmt] => 2022-01-24 12:10:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4029 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [75] => WP_Post Object ( [ID] => 4028 [post_author] => 5 [post_date] => 2021-12-21 11:55:28 [post_date_gmt] => 2021-12-21 11:55:28 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-21 11:56:51 [post_modified_gmt] => 2021-12-21 11:56:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4028 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [76] => WP_Post Object ( [ID] => 4024 [post_author] => 5 [post_date] => 2021-12-15 15:33:17 [post_date_gmt] => 2021-12-15 15:33:17 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22 [to_ping] => [pinged] => [post_modified] => 2021-12-15 15:33:17 [post_modified_gmt] => 2021-12-15 15:33:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4024 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [77] => WP_Post Object ( [ID] => 4022 [post_author] => 5 [post_date] => 2021-12-15 14:49:36 [post_date_gmt] => 2021-12-15 14:49:36 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20 [to_ping] => [pinged] => [post_modified] => 2021-12-15 14:51:23 [post_modified_gmt] => 2021-12-15 14:51:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4022 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [78] => WP_Post Object ( [ID] => 4021 [post_author] => 5 [post_date] => 2021-12-15 14:31:00 [post_date_gmt] => 2021-12-15 14:31:00 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19 [to_ping] => [pinged] => [post_modified] => 2021-12-15 14:31:00 [post_modified_gmt] => 2021-12-15 14:31:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4021 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [79] => WP_Post Object ( [ID] => 4020 [post_author] => 5 [post_date] => 2021-12-15 14:24:47 [post_date_gmt] => 2021-12-15 14:24:47 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18 [to_ping] => [pinged] => [post_modified] => 2021-12-15 14:24:47 [post_modified_gmt] => 2021-12-15 14:24:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4020 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [80] => WP_Post Object ( [ID] => 4017 [post_author] => 5 [post_date] => 2021-12-15 13:22:49 [post_date_gmt] => 2021-12-15 13:22:49 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2021-12-15 13:22:49 [post_modified_gmt] => 2021-12-15 13:22:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4017 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [81] => WP_Post Object ( [ID] => 4016 [post_author] => 5 [post_date] => 2021-12-15 13:20:07 [post_date_gmt] => 2021-12-15 13:20:07 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:34:02 [post_modified_gmt] => 2022-01-27 11:34:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4016 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [82] => WP_Post Object ( [ID] => 4014 [post_author] => 5 [post_date] => 2021-12-15 12:33:09 [post_date_gmt] => 2021-12-15 12:33:09 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2021-12-15 12:33:09 [post_modified_gmt] => 2021-12-15 12:33:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4014 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [83] => WP_Post Object ( [ID] => 4013 [post_author] => 5 [post_date] => 2021-12-15 12:16:20 [post_date_gmt] => 2021-12-15 12:16:20 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2021-12-15 12:17:01 [post_modified_gmt] => 2021-12-15 12:17:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4013 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [84] => WP_Post Object ( [ID] => 4012 [post_author] => 5 [post_date] => 2021-12-15 12:01:13 [post_date_gmt] => 2021-12-15 12:01:13 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-12-15 12:01:13 [post_modified_gmt] => 2021-12-15 12:01:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4012 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [85] => WP_Post Object ( [ID] => 4011 [post_author] => 5 [post_date] => 2021-12-14 15:21:54 [post_date_gmt] => 2021-12-14 15:21:54 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2021-12-15 11:48:20 [post_modified_gmt] => 2021-12-15 11:48:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4011 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [86] => WP_Post Object ( [ID] => 4009 [post_author] => 5 [post_date] => 2021-12-14 15:10:51 [post_date_gmt] => 2021-12-14 15:10:51 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-09 11:00:07 [post_modified_gmt] => 2022-03-09 11:00:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4009 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [87] => WP_Post Object ( [ID] => 4007 [post_author] => 5 [post_date] => 2021-12-14 08:51:32 [post_date_gmt] => 2021-12-14 08:51:32 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-12-14 08:51:44 [post_modified_gmt] => 2021-12-14 08:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4007 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [88] => WP_Post Object ( [ID] => 4006 [post_author] => 5 [post_date] => 2021-12-14 08:16:01 [post_date_gmt] => 2021-12-14 08:16:01 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-23 14:46:11 [post_modified_gmt] => 2022-03-23 14:46:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4006 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [89] => WP_Post Object ( [ID] => 4004 [post_author] => 5 [post_date] => 2021-12-14 07:57:41 [post_date_gmt] => 2021-12-14 07:57:41 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-12-14 07:57:41 [post_modified_gmt] => 2021-12-14 07:57:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4004 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [90] => WP_Post Object ( [ID] => 4003 [post_author] => 5 [post_date] => 2021-12-13 18:36:53 [post_date_gmt] => 2021-12-13 18:36:53 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:25:43 [post_modified_gmt] => 2022-02-11 13:25:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4003 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [91] => WP_Post Object ( [ID] => 4002 [post_author] => 5 [post_date] => 2021-12-13 18:28:05 [post_date_gmt] => 2021-12-13 18:28:05 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2021-12-13 18:41:28 [post_modified_gmt] => 2021-12-13 18:41:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4002 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [92] => WP_Post Object ( [ID] => 4001 [post_author] => 5 [post_date] => 2021-12-13 14:55:46 [post_date_gmt] => 2021-12-13 14:55:46 [post_content] => [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2021-12-13 18:30:22 [post_modified_gmt] => 2021-12-13 18:30:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4001 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [93] => WP_Post Object ( [ID] => 3997 [post_author] => 5 [post_date] => 2021-12-13 14:24:49 [post_date_gmt] => 2021-12-13 14:24:49 [post_content] => [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-13 14:24:59 [post_modified_gmt] => 2021-12-13 14:24:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3997 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [94] => WP_Post Object ( [ID] => 3869 [post_author] => 5 [post_date] => 2021-11-19 12:55:06 [post_date_gmt] => 2021-11-19 12:55:06 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17 [to_ping] => [pinged] => [post_modified] => 2021-12-02 15:02:14 [post_modified_gmt] => 2021-12-02 15:02:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3869 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [95] => WP_Post Object ( [ID] => 3886 [post_author] => 5 [post_date] => 2021-11-18 16:36:37 [post_date_gmt] => 2021-11-18 16:36:37 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-04-12 06:09:26 [post_modified_gmt] => 2022-04-12 06:09:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3886 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [96] => WP_Post Object ( [ID] => 3884 [post_author] => 5 [post_date] => 2021-11-18 16:17:51 [post_date_gmt] => 2021-11-18 16:17:51 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-03-09 11:17:21 [post_modified_gmt] => 2022-03-09 11:17:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3884 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [97] => WP_Post Object ( [ID] => 3883 [post_author] => 5 [post_date] => 2021-11-18 16:10:24 [post_date_gmt] => 2021-11-18 16:10:24 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13 [to_ping] => [pinged] => [post_modified] => 2021-12-03 12:48:26 [post_modified_gmt] => 2021-12-03 12:48:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3883 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [98] => WP_Post Object ( [ID] => 3882 [post_author] => 5 [post_date] => 2021-11-18 16:01:06 [post_date_gmt] => 2021-11-18 16:01:06 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12 [to_ping] => [pinged] => [post_modified] => 2021-12-03 12:49:07 [post_modified_gmt] => 2021-12-03 12:49:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3882 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [99] => WP_Post Object ( [ID] => 3881 [post_author] => 5 [post_date] => 2021-11-18 15:52:45 [post_date_gmt] => 2021-11-18 15:52:45 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-11-18 15:52:45 [post_modified_gmt] => 2021-11-18 15:52:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3881 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [100] => WP_Post Object ( [ID] => 3880 [post_author] => 5 [post_date] => 2021-11-18 15:50:26 [post_date_gmt] => 2021-11-18 15:50:26 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10 [to_ping] => [pinged] => [post_modified] => 2021-11-18 15:50:26 [post_modified_gmt] => 2021-11-18 15:50:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3880 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [101] => WP_Post Object ( [ID] => 3878 [post_author] => 5 [post_date] => 2021-11-18 15:08:19 [post_date_gmt] => 2021-11-18 15:08:19 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-11-18 15:08:19 [post_modified_gmt] => 2021-11-18 15:08:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3878 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [102] => WP_Post Object ( [ID] => 3877 [post_author] => 5 [post_date] => 2021-11-18 15:05:16 [post_date_gmt] => 2021-11-18 15:05:16 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:39:09 [post_modified_gmt] => 2022-01-27 11:39:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3877 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [103] => WP_Post Object ( [ID] => 3876 [post_author] => 5 [post_date] => 2021-11-18 14:51:40 [post_date_gmt] => 2021-11-18 14:51:40 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-11-18 14:51:40 [post_modified_gmt] => 2021-11-18 14:51:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3876 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [104] => WP_Post Object ( [ID] => 3875 [post_author] => 5 [post_date] => 2021-11-18 14:43:39 [post_date_gmt] => 2021-11-18 14:43:39 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-11-22 10:50:23 [post_modified_gmt] => 2021-11-22 10:50:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3875 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [105] => WP_Post Object ( [ID] => 3874 [post_author] => 5 [post_date] => 2021-11-18 14:29:06 [post_date_gmt] => 2021-11-18 14:29:06 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-12 08:08:10 [post_modified_gmt] => 2022-04-12 08:08:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3874 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [106] => WP_Post Object ( [ID] => 3873 [post_author] => 5 [post_date] => 2021-11-18 14:05:12 [post_date_gmt] => 2021-11-18 14:05:12 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-11-19 12:22:45 [post_modified_gmt] => 2021-11-19 12:22:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3873 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [107] => WP_Post Object ( [ID] => 3870 [post_author] => 5 [post_date] => 2021-11-18 12:58:35 [post_date_gmt] => 2021-11-18 12:58:35 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement [to_ping] => [pinged] => [post_modified] => 2021-11-19 12:25:29 [post_modified_gmt] => 2021-11-19 12:25:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3870 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [108] => WP_Post Object ( [ID] => 3863 [post_author] => 5 [post_date] => 2021-11-05 14:19:38 [post_date_gmt] => 2021-11-05 14:19:38 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:22:42 [post_modified_gmt] => 2022-04-18 09:22:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3863 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [109] => WP_Post Object ( [ID] => 3861 [post_author] => 5 [post_date] => 2021-11-05 13:59:54 [post_date_gmt] => 2021-11-05 13:59:54 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:16:26 [post_modified_gmt] => 2022-04-18 07:16:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3861 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [110] => WP_Post Object ( [ID] => 3860 [post_author] => 5 [post_date] => 2021-11-05 13:51:48 [post_date_gmt] => 2021-11-05 13:51:48 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:16:48 [post_modified_gmt] => 2022-04-18 07:16:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3860 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [111] => WP_Post Object ( [ID] => 3859 [post_author] => 5 [post_date] => 2021-11-05 13:44:47 [post_date_gmt] => 2021-11-05 13:44:47 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:28:57 [post_modified_gmt] => 2022-04-18 07:28:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3859 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [112] => WP_Post Object ( [ID] => 3858 [post_author] => 5 [post_date] => 2021-11-05 13:39:37 [post_date_gmt] => 2021-11-05 13:39:37 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:54:11 [post_modified_gmt] => 2022-04-18 07:54:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3858 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [113] => WP_Post Object ( [ID] => 3857 [post_author] => 5 [post_date] => 2021-11-05 13:37:12 [post_date_gmt] => 2021-11-05 13:37:12 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:41:41 [post_modified_gmt] => 2022-04-18 07:41:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3857 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [114] => WP_Post Object ( [ID] => 3856 [post_author] => 5 [post_date] => 2021-11-05 13:12:38 [post_date_gmt] => 2021-11-05 13:12:38 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:11:42 [post_modified_gmt] => 2022-04-18 08:11:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3856 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [115] => WP_Post Object ( [ID] => 3855 [post_author] => 5 [post_date] => 2021-11-05 13:10:25 [post_date_gmt] => 2021-11-05 13:10:25 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:05:19 [post_modified_gmt] => 2022-04-18 08:05:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3855 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [116] => WP_Post Object ( [ID] => 3854 [post_author] => 5 [post_date] => 2021-11-05 13:03:41 [post_date_gmt] => 2021-11-05 13:03:41 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:15:00 [post_modified_gmt] => 2022-04-18 08:15:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3854 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [117] => WP_Post Object ( [ID] => 3852 [post_author] => 5 [post_date] => 2021-11-05 12:43:57 [post_date_gmt] => 2021-11-05 12:43:57 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:33:20 [post_modified_gmt] => 2022-04-18 08:33:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3852 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [118] => WP_Post Object ( [ID] => 3851 [post_author] => 5 [post_date] => 2021-11-05 12:41:54 [post_date_gmt] => 2021-11-05 12:41:54 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:45:20 [post_modified_gmt] => 2022-04-18 08:45:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3851 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [119] => WP_Post Object ( [ID] => 3849 [post_author] => 5 [post_date] => 2021-11-05 12:30:09 [post_date_gmt] => 2021-11-05 12:30:09 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:52:12 [post_modified_gmt] => 2022-04-18 08:52:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3849 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [120] => WP_Post Object ( [ID] => 3848 [post_author] => 5 [post_date] => 2021-11-05 12:27:44 [post_date_gmt] => 2021-11-05 12:27:44 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:58:14 [post_modified_gmt] => 2022-04-18 08:58:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3848 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [121] => WP_Post Object ( [ID] => 3847 [post_author] => 5 [post_date] => 2021-11-05 12:25:40 [post_date_gmt] => 2021-11-05 12:25:40 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:07:16 [post_modified_gmt] => 2022-04-18 09:07:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3847 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [122] => WP_Post Object ( [ID] => 3846 [post_author] => 5 [post_date] => 2021-11-05 12:14:17 [post_date_gmt] => 2021-11-05 12:14:17 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:08:02 [post_modified_gmt] => 2022-04-18 09:08:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3846 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [123] => WP_Post Object ( [ID] => 3845 [post_author] => 5 [post_date] => 2021-11-05 11:56:34 [post_date_gmt] => 2021-11-05 11:56:34 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:20:20 [post_modified_gmt] => 2022-04-18 09:20:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3845 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [124] => WP_Post Object ( [ID] => 3819 [post_author] => 6 [post_date] => 2021-09-15 12:17:55 [post_date_gmt] => 2021-09-15 12:17:55 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-and-gsk-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-15 11:45:22 [post_modified_gmt] => 2021-12-15 11:45:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3819 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [125] => WP_Post Object ( [ID] => 3812 [post_author] => 5 [post_date] => 2021-09-10 12:44:57 [post_date_gmt] => 2021-09-10 12:44:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:13:50 [post_modified_gmt] => 2022-04-20 09:13:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3812 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [126] => WP_Post Object ( [ID] => 3810 [post_author] => 5 [post_date] => 2021-09-10 12:21:33 [post_date_gmt] => 2021-09-10 12:21:33 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:11:54 [post_modified_gmt] => 2022-04-20 07:11:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3810 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [127] => WP_Post Object ( [ID] => 3809 [post_author] => 5 [post_date] => 2021-09-10 12:11:12 [post_date_gmt] => 2021-09-10 12:11:12 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:19:45 [post_modified_gmt] => 2022-04-20 09:19:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3809 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [128] => WP_Post Object ( [ID] => 3808 [post_author] => 5 [post_date] => 2021-09-10 11:59:11 [post_date_gmt] => 2021-09-10 11:59:11 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:24:05 [post_modified_gmt] => 2022-04-20 07:24:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [129] => WP_Post Object ( [ID] => 3807 [post_author] => 5 [post_date] => 2021-09-10 11:55:25 [post_date_gmt] => 2021-09-10 11:55:25 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:42:12 [post_modified_gmt] => 2022-04-20 07:42:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [130] => WP_Post Object ( [ID] => 3806 [post_author] => 5 [post_date] => 2021-09-10 11:47:18 [post_date_gmt] => 2021-09-10 11:47:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:16:48 [post_modified_gmt] => 2022-04-20 09:16:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [131] => WP_Post Object ( [ID] => 3805 [post_author] => 5 [post_date] => 2021-09-10 11:33:53 [post_date_gmt] => 2021-09-10 11:33:53 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:46:59 [post_modified_gmt] => 2022-04-20 07:46:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [132] => WP_Post Object ( [ID] => 3804 [post_author] => 5 [post_date] => 2021-09-10 11:20:59 [post_date_gmt] => 2021-09-10 11:20:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:50:11 [post_modified_gmt] => 2022-04-20 07:50:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [133] => WP_Post Object ( [ID] => 3803 [post_author] => 5 [post_date] => 2021-09-10 10:54:42 [post_date_gmt] => 2021-09-10 10:54:42 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:51:06 [post_modified_gmt] => 2022-04-20 07:51:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3803 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [134] => WP_Post Object ( [ID] => 3802 [post_author] => 5 [post_date] => 2021-09-10 10:45:57 [post_date_gmt] => 2021-09-10 10:45:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:54:14 [post_modified_gmt] => 2022-04-20 07:54:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [135] => WP_Post Object ( [ID] => 3801 [post_author] => 5 [post_date] => 2021-09-10 10:36:30 [post_date_gmt] => 2021-09-10 10:36:30 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:05:17 [post_modified_gmt] => 2022-04-20 08:05:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3801 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [136] => WP_Post Object ( [ID] => 3800 [post_author] => 5 [post_date] => 2021-09-10 10:25:59 [post_date_gmt] => 2021-09-10 10:25:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:35:52 [post_modified_gmt] => 2022-04-20 08:35:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [137] => WP_Post Object ( [ID] => 3799 [post_author] => 5 [post_date] => 2021-09-10 10:07:18 [post_date_gmt] => 2021-09-10 10:07:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:44:40 [post_modified_gmt] => 2022-04-20 08:44:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3799 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [138] => WP_Post Object ( [ID] => 3798 [post_author] => 5 [post_date] => 2021-09-10 10:02:07 [post_date_gmt] => 2021-09-10 10:02:07 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:46:03 [post_modified_gmt] => 2022-04-20 08:46:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [139] => WP_Post Object ( [ID] => 3797 [post_author] => 5 [post_date] => 2021-09-10 09:54:44 [post_date_gmt] => 2021-09-10 09:54:44 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:53:13 [post_modified_gmt] => 2022-04-20 08:53:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3797 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [140] => WP_Post Object ( [ID] => 3796 [post_author] => 5 [post_date] => 2021-09-10 09:03:43 [post_date_gmt] => 2021-09-10 09:03:43 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:07:03 [post_modified_gmt] => 2022-04-20 09:07:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3796 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [141] => WP_Post Object ( [ID] => 3792 [post_author] => 5 [post_date] => 2021-09-09 14:23:13 [post_date_gmt] => 2021-09-09 14:23:13 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 12:44:33 [post_modified_gmt] => 2022-03-09 12:44:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3792 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [142] => WP_Post Object ( [ID] => 3791 [post_author] => 5 [post_date] => 2021-09-09 14:18:44 [post_date_gmt] => 2021-09-09 14:18:44 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:00:35 [post_modified_gmt] => 2021-11-04 09:00:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3791 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [143] => WP_Post Object ( [ID] => 3789 [post_author] => 5 [post_date] => 2021-09-09 14:07:30 [post_date_gmt] => 2021-09-09 14:07:30 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:42:42 [post_modified_gmt] => 2022-01-27 11:42:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3789 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [144] => WP_Post Object ( [ID] => 3788 [post_author] => 5 [post_date] => 2021-09-09 14:00:40 [post_date_gmt] => 2021-09-09 14:00:40 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:02:12 [post_modified_gmt] => 2021-11-04 09:02:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3788 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [145] => WP_Post Object ( [ID] => 3786 [post_author] => 5 [post_date] => 2021-09-09 13:20:21 [post_date_gmt] => 2021-09-09 13:20:21 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-21 13:55:09 [post_modified_gmt] => 2022-03-21 13:55:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3786 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [146] => WP_Post Object ( [ID] => 3785 [post_author] => 5 [post_date] => 2021-09-09 13:10:11 [post_date_gmt] => 2021-09-09 13:10:11 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:04:36 [post_modified_gmt] => 2021-11-04 09:04:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3785 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [147] => WP_Post Object ( [ID] => 3784 [post_author] => 5 [post_date] => 2021-09-09 13:03:52 [post_date_gmt] => 2021-09-09 13:03:52 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:05:12 [post_modified_gmt] => 2021-11-04 09:05:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3784 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [148] => WP_Post Object ( [ID] => 3783 [post_author] => 5 [post_date] => 2021-09-09 12:41:47 [post_date_gmt] => 2021-09-09 12:41:47 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:05:50 [post_modified_gmt] => 2021-11-04 09:05:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3783 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [149] => WP_Post Object ( [ID] => 3782 [post_author] => 5 [post_date] => 2021-09-09 12:36:36 [post_date_gmt] => 2021-09-09 12:36:36 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:50:50 [post_modified_gmt] => 2022-03-28 10:50:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3782 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [150] => WP_Post Object ( [ID] => 3781 [post_author] => 5 [post_date] => 2021-09-09 12:29:54 [post_date_gmt] => 2021-09-09 12:29:54 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:18:43 [post_modified_gmt] => 2021-11-23 14:18:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3781 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [151] => WP_Post Object ( [ID] => 3778 [post_author] => 5 [post_date] => 2021-09-09 11:52:53 [post_date_gmt] => 2021-09-09 11:52:53 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-06 12:35:12 [post_modified_gmt] => 2021-12-06 12:35:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3778 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [152] => WP_Post Object ( [ID] => 3769 [post_author] => 5 [post_date] => 2021-09-02 14:55:06 [post_date_gmt] => 2021-09-02 14:55:06 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-novavax-covid-19-vaccine-development-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-02 15:00:21 [post_modified_gmt] => 2021-12-02 15:00:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3769 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [153] => WP_Post Object ( [ID] => 3768 [post_author] => 5 [post_date] => 2021-09-02 14:27:00 [post_date_gmt] => 2021-09-02 14:27:00 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-12-03 14:19:56 [post_modified_gmt] => 2021-12-03 14:19:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3768 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [154] => WP_Post Object ( [ID] => 3765 [post_author] => 5 [post_date] => 2021-09-01 14:09:03 [post_date_gmt] => 2021-09-01 14:09:03 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:49:00 [post_modified_gmt] => 2022-03-28 10:49:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3765 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [155] => WP_Post Object ( [ID] => 3764 [post_author] => 5 [post_date] => 2021-09-01 12:17:32 [post_date_gmt] => 2021-09-01 12:17:32 [post_content] => [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => barda-moderna-covid-19-vaccine-development-agreement-3 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:15:32 [post_modified_gmt] => 2021-11-23 14:15:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3764 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [156] => WP_Post Object ( [ID] => 3758 [post_author] => 5 [post_date] => 2021-08-26 12:04:03 [post_date_gmt] => 2021-08-26 12:04:03 [post_content] => [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => barda-moderna-covid-19-vaccine-development-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:43:14 [post_modified_gmt] => 2022-03-28 10:43:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3758 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [157] => WP_Post Object ( [ID] => 3741 [post_author] => 5 [post_date] => 2021-08-24 09:13:39 [post_date_gmt] => 2021-08-24 09:13:39 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-04 12:32:22 [post_modified_gmt] => 2022-01-04 12:32:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3741 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [158] => WP_Post Object ( [ID] => 3696 [post_author] => 5 [post_date] => 2021-08-19 14:23:22 [post_date_gmt] => 2021-08-19 14:23:22 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:37:29 [post_modified_gmt] => 2022-01-18 12:37:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3696 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [159] => WP_Post Object ( [ID] => 3495 [post_author] => 5 [post_date] => 2021-08-10 13:06:45 [post_date_gmt] => 2021-08-10 13:06:45 [post_content] => [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dod-moderna-covid-19-vaccine-supply-agreement [to_ping] => [pinged] => [post_modified] => 2021-11-29 14:12:04 [post_modified_gmt] => 2021-11-29 14:12:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3495 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [160] => WP_Post Object ( [ID] => 3493 [post_author] => 5 [post_date] => 2021-08-10 11:15:39 [post_date_gmt] => 2021-08-10 11:15:39 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement [to_ping] => [pinged] => [post_modified] => 2022-02-28 08:24:35 [post_modified_gmt] => 2022-02-28 08:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3493 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [161] => WP_Post Object ( [ID] => 3436 [post_author] => 6 [post_date] => 2021-07-01 03:48:49 [post_date_gmt] => 2021-07-01 03:48:49 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:22:36 [post_modified_gmt] => 2022-04-18 09:22:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3436 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [162] => WP_Post Object ( [ID] => 3434 [post_author] => 6 [post_date] => 2021-07-01 03:44:18 [post_date_gmt] => 2021-07-01 03:44:18 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:28:59 [post_modified_gmt] => 2022-04-18 09:28:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3434 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [163] => WP_Post Object ( [ID] => 3433 [post_author] => 6 [post_date] => 2021-07-01 03:41:21 [post_date_gmt] => 2021-07-01 03:41:21 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:32:11 [post_modified_gmt] => 2022-04-18 09:32:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3433 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [164] => WP_Post Object ( [ID] => 3431 [post_author] => 6 [post_date] => 2021-07-01 03:38:49 [post_date_gmt] => 2021-07-01 03:38:49 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:41:10 [post_modified_gmt] => 2022-04-18 09:41:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3431 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [165] => WP_Post Object ( [ID] => 3430 [post_author] => 6 [post_date] => 2021-07-01 03:27:51 [post_date_gmt] => 2021-07-01 03:27:51 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:45:31 [post_modified_gmt] => 2022-04-18 09:45:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3430 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [166] => WP_Post Object ( [ID] => 3428 [post_author] => 6 [post_date] => 2021-07-01 03:24:00 [post_date_gmt] => 2021-07-01 03:24:00 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:47:22 [post_modified_gmt] => 2022-04-18 09:47:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3428 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [167] => WP_Post Object ( [ID] => 3427 [post_author] => 6 [post_date] => 2021-07-01 03:22:23 [post_date_gmt] => 2021-07-01 03:22:23 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:49:38 [post_modified_gmt] => 2022-04-18 09:49:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3427 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [168] => WP_Post Object ( [ID] => 3426 [post_author] => 6 [post_date] => 2021-07-01 03:06:23 [post_date_gmt] => 2021-07-01 03:06:23 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:28:05 [post_modified_gmt] => 2022-04-18 10:28:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3426 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [169] => WP_Post Object ( [ID] => 3424 [post_author] => 6 [post_date] => 2021-07-01 03:03:57 [post_date_gmt] => 2021-07-01 03:03:57 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:47:10 [post_modified_gmt] => 2022-04-18 10:47:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3424 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [170] => WP_Post Object ( [ID] => 3422 [post_author] => 6 [post_date] => 2021-07-01 02:58:21 [post_date_gmt] => 2021-07-01 02:58:21 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:48:25 [post_modified_gmt] => 2022-04-18 10:48:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3422 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [171] => WP_Post Object ( [ID] => 3421 [post_author] => 6 [post_date] => 2021-07-01 02:56:30 [post_date_gmt] => 2021-07-01 02:56:30 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:51:44 [post_modified_gmt] => 2022-04-18 10:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3421 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [172] => WP_Post Object ( [ID] => 3420 [post_author] => 6 [post_date] => 2021-07-01 02:52:05 [post_date_gmt] => 2021-07-01 02:52:05 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-18 11:01:10 [post_modified_gmt] => 2022-04-18 11:01:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3420 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [173] => WP_Post Object ( [ID] => 3372 [post_author] => 5 [post_date] => 2021-06-30 15:06:19 [post_date_gmt] => 2021-06-30 15:06:19 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:05:39 [post_modified_gmt] => 2022-03-09 13:05:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3372 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [174] => WP_Post Object ( [ID] => 3370 [post_author] => 5 [post_date] => 2021-06-30 15:01:06 [post_date_gmt] => 2021-06-30 15:01:06 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:51:17 [post_modified_gmt] => 2022-01-27 11:51:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3370 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [175] => WP_Post Object ( [ID] => 3368 [post_author] => 5 [post_date] => 2021-06-30 14:58:39 [post_date_gmt] => 2021-06-30 14:58:39 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9 [to_ping] => [pinged] => [post_modified] => 2021-08-24 08:10:31 [post_modified_gmt] => 2021-08-24 08:10:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3368 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [176] => WP_Post Object ( [ID] => 3366 [post_author] => 5 [post_date] => 2021-06-30 14:53:53 [post_date_gmt] => 2021-06-30 14:53:53 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-06-30 14:53:53 [post_modified_gmt] => 2021-06-30 14:53:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3366 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [177] => WP_Post Object ( [ID] => 3364 [post_author] => 5 [post_date] => 2021-06-30 14:47:34 [post_date_gmt] => 2021-06-30 14:47:34 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7 [to_ping] => [pinged] => [post_modified] => 2021-09-02 12:46:22 [post_modified_gmt] => 2021-09-02 12:46:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3364 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [178] => WP_Post Object ( [ID] => 3361 [post_author] => 5 [post_date] => 2021-06-30 14:30:51 [post_date_gmt] => 2021-06-30 14:30:51 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-12-03 14:22:31 [post_modified_gmt] => 2021-12-03 14:22:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3361 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [179] => WP_Post Object ( [ID] => 3360 [post_author] => 5 [post_date] => 2021-06-30 14:28:40 [post_date_gmt] => 2021-06-30 14:28:40 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-12-07 11:53:01 [post_modified_gmt] => 2021-12-07 11:53:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3360 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [180] => WP_Post Object ( [ID] => 3356 [post_author] => 5 [post_date] => 2021-06-30 13:53:23 [post_date_gmt] => 2021-06-30 13:53:23 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:44:11 [post_modified_gmt] => 2022-03-28 10:44:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3356 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [181] => WP_Post Object ( [ID] => 3354 [post_author] => 5 [post_date] => 2021-06-30 13:29:21 [post_date_gmt] => 2021-06-30 13:29:21 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2 [to_ping] => [pinged] => [post_modified] => 2021-06-30 13:29:21 [post_modified_gmt] => 2021-06-30 13:29:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3354 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [182] => WP_Post Object ( [ID] => 3352 [post_author] => 5 [post_date] => 2021-06-30 13:24:49 [post_date_gmt] => 2021-06-30 13:24:49 [post_content] => [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement [to_ping] => [pinged] => [post_modified] => 2022-03-30 12:46:37 [post_modified_gmt] => 2022-03-30 12:46:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3352 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [183] => WP_Post Object ( [ID] => 3221 [post_author] => 6 [post_date] => 2021-06-28 12:23:49 [post_date_gmt] => 2021-06-28 12:23:49 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:24 [post_modified_gmt] => 2021-08-23 09:51:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [184] => WP_Post Object ( [ID] => 3220 [post_author] => 6 [post_date] => 2021-06-28 12:22:09 [post_date_gmt] => 2021-06-28 12:22:09 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:08:44 [post_modified_gmt] => 2022-03-09 13:08:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3220 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [185] => WP_Post Object ( [ID] => 3219 [post_author] => 6 [post_date] => 2021-06-28 12:19:29 [post_date_gmt] => 2021-06-28 12:19:29 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:33 [post_modified_gmt] => 2021-08-23 09:51:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3219 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [186] => WP_Post Object ( [ID] => 3218 [post_author] => 6 [post_date] => 2021-06-28 12:16:20 [post_date_gmt] => 2021-06-28 12:16:20 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:37 [post_modified_gmt] => 2021-08-23 09:51:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3218 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [187] => WP_Post Object ( [ID] => 3217 [post_author] => 6 [post_date] => 2021-06-28 12:14:37 [post_date_gmt] => 2021-06-28 12:14:37 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:41 [post_modified_gmt] => 2021-08-23 09:51:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3217 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [188] => WP_Post Object ( [ID] => 3216 [post_author] => 6 [post_date] => 2021-06-28 12:11:22 [post_date_gmt] => 2021-06-28 12:11:22 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:45 [post_modified_gmt] => 2021-08-23 09:51:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3216 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [189] => WP_Post Object ( [ID] => 3215 [post_author] => 6 [post_date] => 2021-06-28 12:07:55 [post_date_gmt] => 2021-06-28 12:07:55 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:48 [post_modified_gmt] => 2021-08-23 09:51:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3215 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [190] => WP_Post Object ( [ID] => 3127 [post_author] => 6 [post_date] => 2021-06-03 15:08:41 [post_date_gmt] => 2021-06-03 15:08:41 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:52:45 [post_modified_gmt] => 2021-08-23 09:52:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3127 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [191] => WP_Post Object ( [ID] => 3126 [post_author] => 6 [post_date] => 2021-06-03 15:05:40 [post_date_gmt] => 2021-06-03 15:05:40 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:52:49 [post_modified_gmt] => 2021-08-23 09:52:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3126 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [192] => WP_Post Object ( [ID] => 3125 [post_author] => 6 [post_date] => 2021-06-03 15:03:17 [post_date_gmt] => 2021-06-03 15:03:17 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:13:17 [post_modified_gmt] => 2022-03-09 13:13:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3125 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [193] => WP_Post Object ( [ID] => 3124 [post_author] => 6 [post_date] => 2021-06-03 15:01:23 [post_date_gmt] => 2021-06-03 15:01:23 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:52:56 [post_modified_gmt] => 2021-08-23 09:52:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3124 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [194] => WP_Post Object ( [ID] => 3123 [post_author] => 6 [post_date] => 2021-06-03 14:51:22 [post_date_gmt] => 2021-06-03 14:51:22 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5 [to_ping] => [pinged] => [post_modified] => 2021-11-23 13:12:13 [post_modified_gmt] => 2021-11-23 13:12:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3123 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [195] => WP_Post Object ( [ID] => 3122 [post_author] => 6 [post_date] => 2021-06-03 14:45:44 [post_date_gmt] => 2021-06-03 14:45:44 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4 [to_ping] => [pinged] => [post_modified] => 2021-11-23 15:08:08 [post_modified_gmt] => 2021-11-23 15:08:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3122 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [196] => WP_Post Object ( [ID] => 3121 [post_author] => 6 [post_date] => 2021-06-03 14:26:32 [post_date_gmt] => 2021-06-03 14:26:32 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:53:08 [post_modified_gmt] => 2021-08-23 09:53:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3121 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [197] => WP_Post Object ( [ID] => 3120 [post_author] => 6 [post_date] => 2021-06-03 14:24:03 [post_date_gmt] => 2021-06-03 14:24:03 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:53:12 [post_modified_gmt] => 2021-08-23 09:53:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3120 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [198] => WP_Post Object ( [ID] => 3119 [post_author] => 6 [post_date] => 2021-06-03 14:21:50 [post_date_gmt] => 2021-06-03 14:21:50 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:53:15 [post_modified_gmt] => 2021-08-23 09:53:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3119 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [199] => WP_Post Object ( [ID] => 2956 [post_author] => 6 [post_date] => 2021-05-28 18:56:15 [post_date_gmt] => 2021-05-28 18:56:15 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:06 [post_modified_gmt] => 2021-08-23 10:02:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2956 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [200] => WP_Post Object ( [ID] => 2961 [post_author] => 6 [post_date] => 2021-05-28 18:55:47 [post_date_gmt] => 2021-05-28 18:55:47 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11 [to_ping] => [pinged] => [post_modified] => 2021-11-23 12:41:04 [post_modified_gmt] => 2021-11-23 12:41:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2961 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [201] => WP_Post Object ( [ID] => 2965 [post_author] => 6 [post_date] => 2021-05-28 18:55:12 [post_date_gmt] => 2021-05-28 18:55:12 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:15 [post_modified_gmt] => 2021-08-23 10:02:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2965 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [202] => WP_Post Object ( [ID] => 2947 [post_author] => 6 [post_date] => 2021-05-28 18:54:17 [post_date_gmt] => 2021-05-28 18:54:17 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:17 [post_modified_gmt] => 2021-08-23 10:02:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2947 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [203] => WP_Post Object ( [ID] => 2960 [post_author] => 6 [post_date] => 2021-05-28 18:53:36 [post_date_gmt] => 2021-05-28 18:53:36 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:20 [post_modified_gmt] => 2021-08-23 10:02:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2960 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [204] => WP_Post Object ( [ID] => 2964 [post_author] => 6 [post_date] => 2021-05-28 18:53:11 [post_date_gmt] => 2021-05-28 18:53:11 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:24 [post_modified_gmt] => 2021-08-23 10:02:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2964 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [205] => WP_Post Object ( [ID] => 2958 [post_author] => 6 [post_date] => 2021-05-28 18:52:54 [post_date_gmt] => 2021-05-28 18:52:54 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6 [to_ping] => [pinged] => [post_modified] => 2021-12-03 10:13:48 [post_modified_gmt] => 2021-12-03 10:13:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2958 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [206] => WP_Post Object ( [ID] => 2949 [post_author] => 6 [post_date] => 2021-05-28 18:52:06 [post_date_gmt] => 2021-05-28 18:52:06 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5 [to_ping] => [pinged] => [post_modified] => 2021-11-23 12:37:55 [post_modified_gmt] => 2021-11-23 12:37:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2949 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [207] => WP_Post Object ( [ID] => 2957 [post_author] => 6 [post_date] => 2021-05-28 18:51:39 [post_date_gmt] => 2021-05-28 18:51:39 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:00:44 [post_modified_gmt] => 2022-01-27 12:00:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2957 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [208] => WP_Post Object ( [ID] => 2962 [post_author] => 6 [post_date] => 2021-05-28 18:50:18 [post_date_gmt] => 2021-05-28 18:50:18 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3 [to_ping] => [pinged] => [post_modified] => 2021-11-23 12:38:17 [post_modified_gmt] => 2021-11-23 12:38:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2962 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [209] => WP_Post Object ( [ID] => 2945 [post_author] => 6 [post_date] => 2021-05-28 14:03:27 [post_date_gmt] => 2021-05-28 14:03:27 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222 [to_ping] => [pinged] => [post_modified] => 2021-12-03 10:13:02 [post_modified_gmt] => 2021-12-03 10:13:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2945 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [210] => WP_Post Object ( [ID] => 2909 [post_author] => 6 [post_date] => 2021-05-19 15:13:58 [post_date_gmt] => 2021-05-19 15:13:58 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-02-28 08:35:40 [post_modified_gmt] => 2022-02-28 08:35:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2909 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [211] => WP_Post Object ( [ID] => 2908 [post_author] => 6 [post_date] => 2021-05-19 15:08:05 [post_date_gmt] => 2021-05-19 15:08:05 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-02-28 08:59:23 [post_modified_gmt] => 2022-02-28 08:59:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2908 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [212] => WP_Post Object ( [ID] => 2907 [post_author] => 6 [post_date] => 2021-05-19 14:46:20 [post_date_gmt] => 2021-05-19 14:46:20 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-02-28 09:05:23 [post_modified_gmt] => 2022-02-28 09:05:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2907 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [213] => WP_Post Object ( [ID] => 2893 [post_author] => 6 [post_date] => 2021-05-19 14:40:45 [post_date_gmt] => 2021-05-19 14:40:45 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-02-28 09:23:17 [post_modified_gmt] => 2022-02-28 09:23:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2893 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [214] => WP_Post Object ( [ID] => 2892 [post_author] => 6 [post_date] => 2021-05-14 19:30:23 [post_date_gmt] => 2021-05-14 19:30:23 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-01 10:11:21 [post_modified_gmt] => 2022-04-01 10:11:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [215] => WP_Post Object ( [ID] => 2890 [post_author] => 6 [post_date] => 2021-05-14 19:14:07 [post_date_gmt] => 2021-05-14 19:14:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:45:33 [post_modified_gmt] => 2022-03-28 10:45:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [216] => WP_Post Object ( [ID] => 2889 [post_author] => 6 [post_date] => 2021-05-14 19:09:07 [post_date_gmt] => 2021-05-14 19:09:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-02-28 10:58:28 [post_modified_gmt] => 2022-02-28 10:58:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2889 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [217] => WP_Post Object ( [ID] => 2885 [post_author] => 5 [post_date] => 2021-05-14 18:17:37 [post_date_gmt] => 2021-05-14 18:17:37 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement [to_ping] => [pinged] => [post_modified] => 2022-02-28 14:01:15 [post_modified_gmt] => 2022-02-28 14:01:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2885 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [218] => WP_Post Object ( [ID] => 2824 [post_author] => 5 [post_date] => 2021-04-16 16:39:49 [post_date_gmt] => 2021-04-16 16:39:49 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:31:21 [post_modified_gmt] => 2022-01-27 12:31:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2824 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [219] => WP_Post Object ( [ID] => 2823 [post_author] => 5 [post_date] => 2021-04-16 16:17:11 [post_date_gmt] => 2021-04-16 16:17:11 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5 [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:36:43 [post_modified_gmt] => 2022-01-18 12:36:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2823 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [220] => WP_Post Object ( [ID] => 2822 [post_author] => 5 [post_date] => 2021-04-16 16:09:31 [post_date_gmt] => 2021-04-16 16:09:31 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4 [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:48:13 [post_modified_gmt] => 2022-01-18 12:48:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2822 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [221] => WP_Post Object ( [ID] => 2820 [post_author] => 5 [post_date] => 2021-04-16 12:44:14 [post_date_gmt] => 2021-04-16 12:44:14 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2 [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:50:08 [post_modified_gmt] => 2022-01-18 12:50:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2820 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [222] => WP_Post Object ( [ID] => 2744 [post_author] => 5 [post_date] => 2021-03-30 15:12:35 [post_date_gmt] => 2021-03-30 15:12:35 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12 [to_ping] => [pinged] => [post_modified] => 2021-08-12 13:48:08 [post_modified_gmt] => 2021-08-12 13:48:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2744 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [223] => WP_Post Object ( [ID] => 2749 [post_author] => 5 [post_date] => 2021-03-30 15:10:16 [post_date_gmt] => 2021-03-30 15:10:16 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11 [to_ping] => [pinged] => [post_modified] => 2021-08-12 13:54:16 [post_modified_gmt] => 2021-08-12 13:54:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2749 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [224] => WP_Post Object ( [ID] => 2748 [post_author] => 5 [post_date] => 2021-03-30 15:05:46 [post_date_gmt] => 2021-03-30 15:05:46 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => 2748 [to_ping] => [pinged] => [post_modified] => 2021-08-12 13:52:39 [post_modified_gmt] => 2021-08-12 13:52:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2748 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [225] => WP_Post Object ( [ID] => 2743 [post_author] => 5 [post_date] => 2021-03-24 15:11:40 [post_date_gmt] => 2021-03-24 15:11:40 [post_content] => [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:33:45 [post_modified_gmt] => 2022-01-27 12:33:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2743 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [226] => WP_Post Object ( [ID] => 2742 [post_author] => 5 [post_date] => 2021-03-24 13:37:07 [post_date_gmt] => 2021-03-24 13:37:07 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8 [to_ping] => [pinged] => [post_modified] => 2021-08-12 12:28:13 [post_modified_gmt] => 2021-08-12 12:28:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2742 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [227] => WP_Post Object ( [ID] => 2741 [post_author] => 5 [post_date] => 2021-03-24 13:32:55 [post_date_gmt] => 2021-03-24 13:32:55 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7 [to_ping] => [pinged] => [post_modified] => 2021-11-23 15:06:52 [post_modified_gmt] => 2021-11-23 15:06:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2741 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [228] => WP_Post Object ( [ID] => 2739 [post_author] => 5 [post_date] => 2021-03-24 13:12:14 [post_date_gmt] => 2021-03-24 13:12:14 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:47:55 [post_modified_gmt] => 2022-03-28 10:47:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2739 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [229] => WP_Post Object ( [ID] => 2737 [post_author] => 5 [post_date] => 2021-03-24 13:00:46 [post_date_gmt] => 2021-03-24 13:00:46 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4 [to_ping] => [pinged] => [post_modified] => 2021-08-12 12:45:35 [post_modified_gmt] => 2021-08-12 12:45:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2737 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [230] => WP_Post Object ( [ID] => 2736 [post_author] => 5 [post_date] => 2021-03-23 18:15:15 [post_date_gmt] => 2021-03-23 18:15:15 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3 [to_ping] => [pinged] => [post_modified] => 2021-12-03 14:50:37 [post_modified_gmt] => 2021-12-03 14:50:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2736 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [231] => WP_Post Object ( [ID] => 2734 [post_author] => 5 [post_date] => 2021-03-23 18:01:22 [post_date_gmt] => 2021-03-23 18:01:22 [post_content] => [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine [to_ping] => [pinged] => [post_modified] => 2021-09-03 10:29:04 [post_modified_gmt] => 2021-09-03 10:29:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2734 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [232] => WP_Post Object ( [ID] => 2543 [post_author] => 5 [post_date] => 2021-03-12 18:15:58 [post_date_gmt] => 2021-03-12 18:15:58 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-01-04 18:43:53 [post_modified_gmt] => 2022-01-04 18:43:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2543 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [233] => WP_Post Object ( [ID] => 2540 [post_author] => 5 [post_date] => 2021-03-12 18:12:48 [post_date_gmt] => 2021-03-12 18:12:48 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-01-05 09:35:45 [post_modified_gmt] => 2022-01-05 09:35:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2540 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [234] => WP_Post Object ( [ID] => 2541 [post_author] => 5 [post_date] => 2021-03-12 18:11:14 [post_date_gmt] => 2021-03-12 18:11:14 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-05 10:49:36 [post_modified_gmt] => 2022-01-05 10:49:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2541 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [235] => WP_Post Object ( [ID] => 2542 [post_author] => 5 [post_date] => 2021-03-12 14:21:07 [post_date_gmt] => 2021-03-12 14:21:07 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-05 10:17:48 [post_modified_gmt] => 2022-01-05 10:17:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2542 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [236] => WP_Post Object ( [ID] => 2544 [post_author] => 5 [post_date] => 2021-03-12 14:16:06 [post_date_gmt] => 2021-03-12 14:16:06 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:10:55 [post_modified_gmt] => 2022-03-28 10:10:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2544 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [237] => WP_Post Object ( [ID] => 2545 [post_author] => 5 [post_date] => 2021-03-12 14:14:38 [post_date_gmt] => 2021-03-12 14:14:38 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:14:28 [post_modified_gmt] => 2022-03-09 13:14:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2545 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [238] => WP_Post Object ( [ID] => 2547 [post_author] => 5 [post_date] => 2021-03-12 13:58:55 [post_date_gmt] => 2021-03-12 13:58:55 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:38:40 [post_modified_gmt] => 2022-01-27 12:38:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2547 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [239] => WP_Post Object ( [ID] => 2549 [post_author] => 5 [post_date] => 2021-03-12 13:50:41 [post_date_gmt] => 2021-03-12 13:50:41 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-05 08:48:43 [post_modified_gmt] => 2022-01-05 08:48:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2549 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [240] => WP_Post Object ( [ID] => 2553 [post_author] => 5 [post_date] => 2021-03-12 13:47:42 [post_date_gmt] => 2021-03-12 13:47:42 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-05 10:59:58 [post_modified_gmt] => 2022-01-05 10:59:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2553 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [241] => WP_Post Object ( [ID] => 2457 [post_author] => 5 [post_date] => 2021-02-25 15:25:57 [post_date_gmt] => 2021-02-25 15:25:57 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10 [to_ping] => [pinged] => [post_modified] => 2021-09-03 12:14:51 [post_modified_gmt] => 2021-09-03 12:14:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2457 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [242] => WP_Post Object ( [ID] => 2461 [post_author] => 5 [post_date] => 2021-02-25 15:23:35 [post_date_gmt] => 2021-02-25 15:23:35 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7 [to_ping] => [pinged] => [post_modified] => 2021-08-24 08:19:55 [post_modified_gmt] => 2021-08-24 08:19:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2461 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [243] => WP_Post Object ( [ID] => 2462 [post_author] => 5 [post_date] => 2021-02-25 15:23:19 [post_date_gmt] => 2021-02-25 15:23:19 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6 [to_ping] => [pinged] => [post_modified] => 2021-09-03 13:28:17 [post_modified_gmt] => 2021-09-03 13:28:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2462 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [244] => WP_Post Object ( [ID] => 2463 [post_author] => 5 [post_date] => 2021-02-25 15:22:52 [post_date_gmt] => 2021-02-25 15:22:52 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5 [to_ping] => [pinged] => [post_modified] => 2021-09-03 13:35:23 [post_modified_gmt] => 2021-09-03 13:35:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2463 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [245] => WP_Post Object ( [ID] => 2464 [post_author] => 5 [post_date] => 2021-02-25 15:21:51 [post_date_gmt] => 2021-02-25 15:21:51 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4 [to_ping] => [pinged] => [post_modified] => 2021-11-23 15:13:03 [post_modified_gmt] => 2021-11-23 15:13:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2464 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [246] => WP_Post Object ( [ID] => 2465 [post_author] => 5 [post_date] => 2021-02-25 15:21:32 [post_date_gmt] => 2021-02-25 15:21:32 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:40:25 [post_modified_gmt] => 2022-01-27 12:40:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2465 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [247] => WP_Post Object ( [ID] => 2466 [post_author] => 5 [post_date] => 2021-02-25 15:20:40 [post_date_gmt] => 2021-02-25 15:20:40 [post_content] => [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:50:01 [post_modified_gmt] => 2022-03-28 10:50:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2466 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [248] => WP_Post Object ( [ID] => 2467 [post_author] => 5 [post_date] => 2021-02-25 15:20:15 [post_date_gmt] => 2021-02-25 15:20:15 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:15:33 [post_modified_gmt] => 2022-03-09 13:15:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2467 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [249] => WP_Post Object ( [ID] => 2470 [post_author] => 5 [post_date] => 2021-01-25 13:24:13 [post_date_gmt] => 2021-01-25 13:24:13 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-03-28 13:54:22 [post_modified_gmt] => 2022-03-28 13:54:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2470 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [250] => WP_Post Object ( [ID] => 2473 [post_author] => 5 [post_date] => 2021-01-25 13:21:58 [post_date_gmt] => 2021-01-25 13:21:58 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-01-04 14:14:59 [post_modified_gmt] => 2022-01-04 14:14:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2473 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [251] => WP_Post Object ( [ID] => 2474 [post_author] => 5 [post_date] => 2021-01-25 13:19:34 [post_date_gmt] => 2021-01-25 13:19:34 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-01-04 12:54:44 [post_modified_gmt] => 2022-01-04 12:54:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2474 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [252] => WP_Post Object ( [ID] => 2475 [post_author] => 5 [post_date] => 2021-01-25 13:18:53 [post_date_gmt] => 2021-01-25 13:18:53 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-04 11:57:00 [post_modified_gmt] => 2022-01-04 11:57:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2475 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [253] => WP_Post Object ( [ID] => 2476 [post_author] => 5 [post_date] => 2021-01-25 13:18:09 [post_date_gmt] => 2021-01-25 13:18:09 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-04 12:42:48 [post_modified_gmt] => 2022-01-04 12:42:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2476 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [254] => WP_Post Object ( [ID] => 2477 [post_author] => 5 [post_date] => 2021-01-25 13:16:23 [post_date_gmt] => 2021-01-25 13:16:23 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:38:40 [post_modified_gmt] => 2022-03-08 13:38:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2477 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [255] => WP_Post Object ( [ID] => 2479 [post_author] => 5 [post_date] => 2021-01-25 13:12:32 [post_date_gmt] => 2021-01-25 13:12:32 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:42:15 [post_modified_gmt] => 2022-01-27 12:42:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2479 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [256] => WP_Post Object ( [ID] => 2481 [post_author] => 5 [post_date] => 2021-01-25 13:11:08 [post_date_gmt] => 2021-01-25 13:11:08 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-01-19 10:39:14 [post_modified_gmt] => 2022-01-19 10:39:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2481 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [257] => WP_Post Object ( [ID] => 2482 [post_author] => 5 [post_date] => 2021-01-25 13:09:37 [post_date_gmt] => 2021-01-25 13:09:37 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-04 14:23:50 [post_modified_gmt] => 2022-01-04 14:23:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2482 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [258] => WP_Post Object ( [ID] => 2471 [post_author] => 5 [post_date] => 2021-01-25 13:08:02 [post_date_gmt] => 2021-01-25 13:08:02 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-04 13:51:57 [post_modified_gmt] => 2022-01-04 13:51:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2471 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [259] => WP_Post Object ( [ID] => 2454 [post_author] => 5 [post_date] => 2021-01-19 11:44:16 [post_date_gmt] => 2021-01-19 11:44:16 [post_content] => [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:28:26 [post_modified_gmt] => 2021-11-23 14:28:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2454 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [260] => WP_Post Object ( [ID] => 2452 [post_author] => 5 [post_date] => 2021-01-19 11:41:19 [post_date_gmt] => 2021-01-19 11:41:19 [post_content] => [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:12:55 [post_modified_gmt] => 2022-03-28 10:12:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2452 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [261] => WP_Post Object ( [ID] => 2450 [post_author] => 5 [post_date] => 2021-01-19 11:04:23 [post_date_gmt] => 2021-01-19 11:04:23 [post_content] => [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:46:34 [post_modified_gmt] => 2022-01-27 12:46:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2450 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [262] => WP_Post Object ( [ID] => 2449 [post_author] => 5 [post_date] => 2021-01-19 10:47:27 [post_date_gmt] => 2021-01-19 10:47:27 [post_content] => [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:29:46 [post_modified_gmt] => 2021-11-23 14:29:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2449 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [263] => WP_Post Object ( [ID] => 2448 [post_author] => 5 [post_date] => 2021-01-19 10:24:45 [post_date_gmt] => 2021-01-19 10:24:45 [post_content] => [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:29:52 [post_modified_gmt] => 2021-11-23 14:29:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2448 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [264] => WP_Post Object ( [ID] => 2444 [post_author] => 5 [post_date] => 2021-01-19 09:27:20 [post_date_gmt] => 2021-01-19 09:27:20 [post_content] => [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:42:37 [post_modified_gmt] => 2022-03-08 13:42:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2444 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [265] => WP_Post Object ( [ID] => 2443 [post_author] => 5 [post_date] => 2021-01-19 09:14:03 [post_date_gmt] => 2021-01-19 09:14:03 [post_content] => [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:17:16 [post_modified_gmt] => 2021-11-23 14:17:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2443 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [266] => WP_Post Object ( [ID] => 2442 [post_author] => 5 [post_date] => 2021-01-19 06:56:32 [post_date_gmt] => 2021-01-19 06:56:32 [post_content] => [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3 [to_ping] => [pinged] => [post_modified] => 2021-12-08 11:02:27 [post_modified_gmt] => 2021-12-08 11:02:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2442 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [267] => WP_Post Object ( [ID] => 2441 [post_author] => 5 [post_date] => 2021-01-19 06:48:04 [post_date_gmt] => 2021-01-19 06:48:04 [post_content] => [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:47:37 [post_modified_gmt] => 2022-01-27 12:47:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2441 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [268] => WP_Post Object ( [ID] => 2426 [post_author] => 5 [post_date] => 2020-12-14 15:02:08 [post_date_gmt] => 2020-12-14 15:02:08 [post_content] => [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3 [to_ping] => [pinged] => [post_modified] => 2021-12-07 11:44:08 [post_modified_gmt] => 2021-12-07 11:44:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2426 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [269] => WP_Post Object ( [ID] => 2424 [post_author] => 5 [post_date] => 2020-12-14 15:01:40 [post_date_gmt] => 2020-12-14 15:01:40 [post_content] => [post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2 [to_ping] => [pinged] => [post_modified] => 2021-11-23 12:46:03 [post_modified_gmt] => 2021-11-23 12:46:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2424 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [270] => WP_Post Object ( [ID] => 3909 [post_author] => 5 [post_date] => 2021-11-22 13:29:28 [post_date_gmt] => 2021-11-22 13:29:28 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-03-09 11:13:09 [post_modified_gmt] => 2022-03-09 11:13:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3909 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [271] => WP_Post Object ( [ID] => 3908 [post_author] => 5 [post_date] => 2021-11-22 13:20:09 [post_date_gmt] => 2021-11-22 13:20:09 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:28:33 [post_modified_gmt] => 2022-02-11 13:28:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3908 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [272] => WP_Post Object ( [ID] => 3906 [post_author] => 5 [post_date] => 2021-11-22 12:57:50 [post_date_gmt] => 2021-11-22 12:57:50 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:22:44 [post_modified_gmt] => 2022-01-31 15:22:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3906 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [273] => WP_Post Object ( [ID] => 3904 [post_author] => 5 [post_date] => 2021-11-22 12:20:20 [post_date_gmt] => 2021-11-22 12:20:20 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:00 [post_modified_gmt] => 2022-01-31 15:23:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3904 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [274] => WP_Post Object ( [ID] => 3903 [post_author] => 5 [post_date] => 2021-11-22 12:04:07 [post_date_gmt] => 2021-11-22 12:04:07 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:16 [post_modified_gmt] => 2022-01-31 15:23:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3903 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [275] => WP_Post Object ( [ID] => 3901 [post_author] => 5 [post_date] => 2021-11-22 11:42:55 [post_date_gmt] => 2021-11-22 11:42:55 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:34 [post_modified_gmt] => 2022-01-31 15:23:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3901 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [276] => WP_Post Object ( [ID] => 3900 [post_author] => 5 [post_date] => 2021-11-22 11:35:10 [post_date_gmt] => 2021-11-22 11:35:10 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:52 [post_modified_gmt] => 2022-01-31 15:23:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3900 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [277] => WP_Post Object ( [ID] => 3899 [post_author] => 5 [post_date] => 2021-11-22 11:24:36 [post_date_gmt] => 2021-11-22 11:24:36 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-21 13:42:51 [post_modified_gmt] => 2022-03-21 13:42:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3899 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [278] => WP_Post Object ( [ID] => 3898 [post_author] => 5 [post_date] => 2021-11-22 11:02:44 [post_date_gmt] => 2021-11-22 11:02:44 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:24:53 [post_modified_gmt] => 2022-01-31 15:24:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3898 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [279] => WP_Post Object ( [ID] => 3897 [post_author] => 5 [post_date] => 2021-11-22 10:34:34 [post_date_gmt] => 2021-11-22 10:34:34 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:25:11 [post_modified_gmt] => 2022-01-31 15:25:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3897 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [280] => WP_Post Object ( [ID] => 3896 [post_author] => 5 [post_date] => 2021-11-22 10:27:28 [post_date_gmt] => 2021-11-22 10:27:28 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:25:40 [post_modified_gmt] => 2022-01-31 15:25:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3896 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [281] => WP_Post Object ( [ID] => 3895 [post_author] => 5 [post_date] => 2021-11-22 10:20:20 [post_date_gmt] => 2021-11-22 10:20:20 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-01 09:51:43 [post_modified_gmt] => 2022-04-01 09:51:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3895 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [282] => WP_Post Object ( [ID] => 3892 [post_author] => 5 [post_date] => 2021-11-19 13:53:26 [post_date_gmt] => 2021-11-19 13:53:26 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:26:44 [post_modified_gmt] => 2022-01-31 15:26:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [283] => WP_Post Object ( [ID] => 3891 [post_author] => 5 [post_date] => 2021-11-19 13:11:12 [post_date_gmt] => 2021-11-19 13:11:12 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:27:01 [post_modified_gmt] => 2022-01-31 15:27:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3891 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [284] => WP_Post Object ( [ID] => 3890 [post_author] => 5 [post_date] => 2021-11-19 13:00:24 [post_date_gmt] => 2021-11-19 13:00:24 [post_content] => [post_title] => MSD - MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:27:21 [post_modified_gmt] => 2022-01-31 15:27:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [285] => WP_Post Object ( [ID] => 3418 [post_author] => 5 [post_date] => 2021-06-30 19:06:19 [post_date_gmt] => 2021-06-30 19:06:19 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:03:49 [post_modified_gmt] => 2022-03-09 13:03:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3418 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [286] => WP_Post Object ( [ID] => 3417 [post_author] => 5 [post_date] => 2021-06-30 19:04:34 [post_date_gmt] => 2021-06-30 19:04:34 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:12:39 [post_modified_gmt] => 2021-09-01 15:12:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3417 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [287] => WP_Post Object ( [ID] => 3416 [post_author] => 5 [post_date] => 2021-06-30 19:02:19 [post_date_gmt] => 2021-06-30 19:02:19 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:12:57 [post_modified_gmt] => 2021-09-01 15:12:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3416 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [288] => WP_Post Object ( [ID] => 3415 [post_author] => 5 [post_date] => 2021-06-30 19:00:20 [post_date_gmt] => 2021-06-30 19:00:20 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2021-11-30 12:40:36 [post_modified_gmt] => 2021-11-30 12:40:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3415 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [289] => WP_Post Object ( [ID] => 3414 [post_author] => 5 [post_date] => 2021-06-30 18:54:43 [post_date_gmt] => 2021-06-30 18:54:43 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:08:59 [post_modified_gmt] => 2021-09-01 15:08:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3414 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [290] => WP_Post Object ( [ID] => 3413 [post_author] => 5 [post_date] => 2021-06-30 18:52:08 [post_date_gmt] => 2021-06-30 18:52:08 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:10:41 [post_modified_gmt] => 2021-09-01 15:10:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3413 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [291] => WP_Post Object ( [ID] => 3412 [post_author] => 5 [post_date] => 2021-06-30 18:48:13 [post_date_gmt] => 2021-06-30 18:48:13 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:32:40 [post_modified_gmt] => 2022-02-11 13:32:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3412 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [292] => WP_Post Object ( [ID] => 3411 [post_author] => 5 [post_date] => 2021-06-30 18:39:53 [post_date_gmt] => 2021-06-30 18:39:53 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:11:28 [post_modified_gmt] => 2021-09-01 15:11:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3411 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [293] => WP_Post Object ( [ID] => 3410 [post_author] => 5 [post_date] => 2021-06-30 18:37:02 [post_date_gmt] => 2021-06-30 18:37:02 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:09:38 [post_modified_gmt] => 2021-09-01 15:09:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3410 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [294] => WP_Post Object ( [ID] => 3409 [post_author] => 5 [post_date] => 2021-06-30 18:34:04 [post_date_gmt] => 2021-06-30 18:34:04 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-24 12:58:15 [post_modified_gmt] => 2022-01-24 12:58:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3409 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [295] => WP_Post Object ( [ID] => 3406 [post_author] => 5 [post_date] => 2021-06-30 18:25:58 [post_date_gmt] => 2021-06-30 18:25:58 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:11:44 [post_modified_gmt] => 2021-09-01 15:11:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3406 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [296] => WP_Post Object ( [ID] => 3304 [post_author] => 6 [post_date] => 2021-06-30 09:30:56 [post_date_gmt] => 2021-06-30 09:30:56 [post_content] => [post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:01:21 [post_modified_gmt] => 2021-08-23 10:01:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3304 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [297] => WP_Post Object ( [ID] => 2873 [post_author] => 6 [post_date] => 2021-05-11 15:17:08 [post_date_gmt] => 2021-05-11 15:17:08 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-11-22 15:50:47 [post_modified_gmt] => 2021-11-22 15:50:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2873 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [298] => WP_Post Object ( [ID] => 2872 [post_author] => 6 [post_date] => 2021-05-11 15:14:24 [post_date_gmt] => 2021-05-11 15:14:24 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-12-06 12:00:31 [post_modified_gmt] => 2021-12-06 12:00:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2872 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [299] => WP_Post Object ( [ID] => 2870 [post_author] => 6 [post_date] => 2021-05-11 15:07:59 [post_date_gmt] => 2021-05-11 15:07:59 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-06-15 09:15:21 [post_modified_gmt] => 2021-06-15 09:15:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2870 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [300] => WP_Post Object ( [ID] => 2869 [post_author] => 6 [post_date] => 2021-05-11 14:53:04 [post_date_gmt] => 2021-05-11 14:53:04 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3 [to_ping] => [pinged] => [post_modified] => 2021-05-14 09:15:00 [post_modified_gmt] => 2021-05-14 09:15:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2869 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [301] => WP_Post Object ( [ID] => 2867 [post_author] => 6 [post_date] => 2021-05-11 14:28:02 [post_date_gmt] => 2021-05-11 14:28:02 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => 2867 [to_ping] => [pinged] => [post_modified] => 2022-05-24 12:12:41 [post_modified_gmt] => 2022-05-24 12:12:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2867 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 302 [current_post] => -1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4808 [post_author] => 5 [post_date] => 2022-05-24 09:09:54 [post_date_gmt] => 2022-05-24 09:09:54 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-05-24 09:09:54 [post_modified_gmt] => 2022-05-24 09:09:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 302 [max_num_pages] => 0 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => 1 [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => 1 [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => 1 [query_vars_hash:WP_Query:private] => b1050dec43e5eb51fb39662feaeb2b86 [query_vars_changed:WP_Query:private] => 1 [thumbnails_cached] => [stopwords:WP_Query:private] => Array ( [0] => about [1] => an [2] => are [3] => as [4] => at [5] => be [6] => by [7] => com [8] => for [9] => from [10] => how [11] => in [12] => is [13] => it [14] => of [15] => on [16] => or [17] => that [18] => the [19] => this [20] => to [21] => was [22] => what [23] => when [24] => where [25] => who [26] => will [27] => with [28] => www ) [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) ) [provisions] => Array ( [0] => WP_Post Object ( [ID] => 4808 [post_author] => 5 [post_date] => 2022-05-24 09:09:54 [post_date_gmt] => 2022-05-24 09:09:54 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-05-24 09:09:54 [post_modified_gmt] => 2022-05-24 09:09:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4807 [post_author] => 5 [post_date] => 2022-05-24 09:02:55 [post_date_gmt] => 2022-05-24 09:02:55 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-05-24 09:02:55 [post_modified_gmt] => 2022-05-24 09:02:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 4806 [post_author] => 5 [post_date] => 2022-05-24 08:59:08 [post_date_gmt] => 2022-05-24 08:59:08 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:59:08 [post_modified_gmt] => 2022-05-24 08:59:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 4805 [post_author] => 5 [post_date] => 2022-05-24 08:53:12 [post_date_gmt] => 2022-05-24 08:53:12 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:59:42 [post_modified_gmt] => 2022-05-24 08:59:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 4804 [post_author] => 5 [post_date] => 2022-05-24 08:40:15 [post_date_gmt] => 2022-05-24 08:40:15 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:53:51 [post_modified_gmt] => 2022-05-24 08:53:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [5] => WP_Post Object ( [ID] => 4802 [post_author] => 5 [post_date] => 2022-05-24 08:24:23 [post_date_gmt] => 2022-05-24 08:24:23 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:24:23 [post_modified_gmt] => 2022-05-24 08:24:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [6] => WP_Post Object ( [ID] => 4801 [post_author] => 5 [post_date] => 2022-05-24 08:19:21 [post_date_gmt] => 2022-05-24 08:19:21 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:19:21 [post_modified_gmt] => 2022-05-24 08:19:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4801 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [7] => WP_Post Object ( [ID] => 4800 [post_author] => 5 [post_date] => 2022-05-24 08:07:39 [post_date_gmt] => 2022-05-24 08:07:39 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-05-24 08:08:30 [post_modified_gmt] => 2022-05-24 08:08:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [8] => WP_Post Object ( [ID] => 4798 [post_author] => 5 [post_date] => 2022-05-23 14:11:13 [post_date_gmt] => 2022-05-23 14:11:13 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-05-23 14:12:44 [post_modified_gmt] => 2022-05-23 14:12:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [9] => WP_Post Object ( [ID] => 4797 [post_author] => 5 [post_date] => 2022-05-23 13:54:57 [post_date_gmt] => 2022-05-23 13:54:57 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-05-23 13:54:57 [post_modified_gmt] => 2022-05-23 13:54:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4797 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [10] => WP_Post Object ( [ID] => 4796 [post_author] => 5 [post_date] => 2022-05-23 13:54:05 [post_date_gmt] => 2022-05-23 13:54:05 [post_content] => [post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-05-23 14:21:34 [post_modified_gmt] => 2022-05-23 14:21:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4796 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [11] => WP_Post Object ( [ID] => 4661 [post_author] => 5 [post_date] => 2022-04-20 08:13:06 [post_date_gmt] => 2022-04-20 08:13:06 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:13:06 [post_modified_gmt] => 2022-04-20 08:13:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4661 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [12] => WP_Post Object ( [ID] => 4147 [post_author] => 5 [post_date] => 2022-04-18 12:53:51 [post_date_gmt] => 2022-04-18 12:53:51 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:22:54 [post_modified_gmt] => 2022-04-18 13:22:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4147 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [13] => WP_Post Object ( [ID] => 4601 [post_author] => 5 [post_date] => 2022-04-18 10:40:48 [post_date_gmt] => 2022-04-18 10:40:48 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:44:46 [post_modified_gmt] => 2022-04-18 10:44:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4601 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [14] => WP_Post Object ( [ID] => 4148 [post_author] => 5 [post_date] => 2022-04-12 08:59:45 [post_date_gmt] => 2022-04-12 08:59:45 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:55:19 [post_modified_gmt] => 2022-04-18 13:55:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4148 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [15] => WP_Post Object ( [ID] => 4223 [post_author] => 5 [post_date] => 2022-03-04 09:43:58 [post_date_gmt] => 2022-03-04 09:43:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-03-04 09:43:58 [post_modified_gmt] => 2022-03-04 09:43:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4223 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [16] => WP_Post Object ( [ID] => 4222 [post_author] => 5 [post_date] => 2022-03-04 09:14:41 [post_date_gmt] => 2022-03-04 09:14:41 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:51:38 [post_modified_gmt] => 2022-03-08 13:51:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4222 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [17] => WP_Post Object ( [ID] => 4221 [post_author] => 5 [post_date] => 2022-03-04 09:05:29 [post_date_gmt] => 2022-03-04 09:05:29 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-04 09:05:29 [post_modified_gmt] => 2022-03-04 09:05:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [18] => WP_Post Object ( [ID] => 4220 [post_author] => 5 [post_date] => 2022-03-04 08:47:04 [post_date_gmt] => 2022-03-04 08:47:04 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-03-04 08:47:04 [post_modified_gmt] => 2022-03-04 08:47:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4220 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [19] => WP_Post Object ( [ID] => 4219 [post_author] => 5 [post_date] => 2022-03-04 08:02:15 [post_date_gmt] => 2022-03-04 08:02:15 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-03-04 08:47:42 [post_modified_gmt] => 2022-03-04 08:47:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4219 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [20] => WP_Post Object ( [ID] => 4218 [post_author] => 5 [post_date] => 2022-03-03 14:17:53 [post_date_gmt] => 2022-03-03 14:17:53 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-03-03 14:17:53 [post_modified_gmt] => 2022-03-03 14:17:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4218 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [21] => WP_Post Object ( [ID] => 4217 [post_author] => 5 [post_date] => 2022-03-03 13:59:58 [post_date_gmt] => 2022-03-03 13:59:58 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-03 14:11:50 [post_modified_gmt] => 2022-03-03 14:11:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4217 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [22] => WP_Post Object ( [ID] => 4216 [post_author] => 5 [post_date] => 2022-03-03 13:45:21 [post_date_gmt] => 2022-03-03 13:45:21 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-03 13:45:46 [post_modified_gmt] => 2022-03-03 13:45:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4216 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [23] => WP_Post Object ( [ID] => 4215 [post_author] => 5 [post_date] => 2022-03-03 13:31:56 [post_date_gmt] => 2022-03-03 13:31:56 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-03-03 13:42:58 [post_modified_gmt] => 2022-03-03 13:42:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4215 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [24] => WP_Post Object ( [ID] => 4214 [post_author] => 5 [post_date] => 2022-03-03 12:54:33 [post_date_gmt] => 2022-03-03 12:54:33 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-03-21 13:17:07 [post_modified_gmt] => 2022-03-21 13:17:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4214 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [25] => WP_Post Object ( [ID] => 4213 [post_author] => 5 [post_date] => 2022-03-03 10:54:01 [post_date_gmt] => 2022-03-03 10:54:01 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-03-03 10:58:00 [post_modified_gmt] => 2022-03-03 10:58:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4213 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [26] => WP_Post Object ( [ID] => 4212 [post_author] => 5 [post_date] => 2022-03-02 14:54:16 [post_date_gmt] => 2022-03-02 14:54:16 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:51:03 [post_modified_gmt] => 2022-03-08 13:51:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4212 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [27] => WP_Post Object ( [ID] => 4210 [post_author] => 5 [post_date] => 2022-03-02 13:14:31 [post_date_gmt] => 2022-03-02 13:14:31 [post_content] => [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-02 13:14:31 [post_modified_gmt] => 2022-03-02 13:14:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4210 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [28] => WP_Post Object ( [ID] => 4209 [post_author] => 5 [post_date] => 2022-03-02 12:07:13 [post_date_gmt] => 2022-03-02 12:07:13 [post_content] => [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement [to_ping] => [pinged] => [post_modified] => 2022-03-04 10:05:30 [post_modified_gmt] => 2022-03-04 10:05:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4209 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [29] => WP_Post Object ( [ID] => 4205 [post_author] => 5 [post_date] => 2022-02-28 15:24:19 [post_date_gmt] => 2022-02-28 15:24:19 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-02-28 15:24:19 [post_modified_gmt] => 2022-02-28 15:24:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4205 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [30] => WP_Post Object ( [ID] => 4204 [post_author] => 5 [post_date] => 2022-02-28 14:53:11 [post_date_gmt] => 2022-02-28 14:53:11 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-02-28 14:53:11 [post_modified_gmt] => 2022-02-28 14:53:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4204 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [31] => WP_Post Object ( [ID] => 4201 [post_author] => 5 [post_date] => 2022-02-28 13:33:22 [post_date_gmt] => 2022-02-28 13:33:22 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-02-28 14:46:09 [post_modified_gmt] => 2022-02-28 14:46:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4201 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [32] => WP_Post Object ( [ID] => 4200 [post_author] => 5 [post_date] => 2022-02-28 13:13:29 [post_date_gmt] => 2022-02-28 13:13:29 [post_content] => [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:54:57 [post_modified_gmt] => 2022-03-08 13:54:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4200 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [33] => WP_Post Object ( [ID] => 4161 [post_author] => 5 [post_date] => 2022-02-02 13:48:58 [post_date_gmt] => 2022-02-02 13:48:58 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:17:00 [post_modified_gmt] => 2022-04-18 13:17:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4161 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [34] => WP_Post Object ( [ID] => 4159 [post_author] => 5 [post_date] => 2022-02-02 13:10:48 [post_date_gmt] => 2022-02-02 13:10:48 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:16:05 [post_modified_gmt] => 2022-04-18 13:16:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4159 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [35] => WP_Post Object ( [ID] => 4158 [post_author] => 5 [post_date] => 2022-02-02 13:00:08 [post_date_gmt] => 2022-02-02 13:00:08 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:15:30 [post_modified_gmt] => 2022-04-18 13:15:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4158 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [36] => WP_Post Object ( [ID] => 4157 [post_author] => 5 [post_date] => 2022-02-02 12:54:56 [post_date_gmt] => 2022-02-02 12:54:56 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:13:37 [post_modified_gmt] => 2022-04-18 13:13:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4157 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [37] => WP_Post Object ( [ID] => 4156 [post_author] => 5 [post_date] => 2022-02-02 12:36:42 [post_date_gmt] => 2022-02-02 12:36:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:12:51 [post_modified_gmt] => 2022-04-18 13:12:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4156 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [38] => WP_Post Object ( [ID] => 4155 [post_author] => 5 [post_date] => 2022-02-02 12:19:16 [post_date_gmt] => 2022-02-02 12:19:16 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:12:26 [post_modified_gmt] => 2022-04-18 13:12:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4155 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [39] => WP_Post Object ( [ID] => 4154 [post_author] => 5 [post_date] => 2022-02-02 12:13:41 [post_date_gmt] => 2022-02-02 12:13:41 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-02-02 12:13:41 [post_modified_gmt] => 2022-02-02 12:13:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4154 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [40] => WP_Post Object ( [ID] => 4153 [post_author] => 5 [post_date] => 2022-02-02 12:10:13 [post_date_gmt] => 2022-02-02 12:10:13 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:02:30 [post_modified_gmt] => 2022-04-18 13:02:30 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4153 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [41] => WP_Post Object ( [ID] => 4152 [post_author] => 5 [post_date] => 2022-02-02 11:51:54 [post_date_gmt] => 2022-02-02 11:51:54 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:02:06 [post_modified_gmt] => 2022-04-18 13:02:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4152 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [42] => WP_Post Object ( [ID] => 4151 [post_author] => 5 [post_date] => 2022-02-02 11:39:24 [post_date_gmt] => 2022-02-02 11:39:24 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:01:35 [post_modified_gmt] => 2022-04-18 13:01:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4151 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [43] => WP_Post Object ( [ID] => 4150 [post_author] => 5 [post_date] => 2022-02-02 10:24:30 [post_date_gmt] => 2022-02-02 10:24:30 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:01:03 [post_modified_gmt] => 2022-04-18 13:01:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4150 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [44] => WP_Post Object ( [ID] => 4149 [post_author] => 5 [post_date] => 2022-02-02 10:15:42 [post_date_gmt] => 2022-02-02 10:15:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-18 13:00:34 [post_modified_gmt] => 2022-04-18 13:00:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4149 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [45] => WP_Post Object ( [ID] => 4146 [post_author] => 5 [post_date] => 2022-02-02 07:28:42 [post_date_gmt] => 2022-02-02 07:28:42 [post_content] => [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-18 12:57:05 [post_modified_gmt] => 2022-04-18 12:57:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4146 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [46] => WP_Post Object ( [ID] => 4141 [post_author] => 5 [post_date] => 2022-01-31 14:31:23 [post_date_gmt] => 2022-01-31 14:31:23 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-01-31 14:33:23 [post_modified_gmt] => 2022-01-31 14:33:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4141 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [47] => WP_Post Object ( [ID] => 4140 [post_author] => 5 [post_date] => 2022-01-31 14:22:03 [post_date_gmt] => 2022-01-31 14:22:03 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:11:05 [post_modified_gmt] => 2022-03-09 13:11:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4140 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [48] => WP_Post Object ( [ID] => 4139 [post_author] => 5 [post_date] => 2022-01-31 14:18:32 [post_date_gmt] => 2022-01-31 14:18:32 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-02-11 11:35:27 [post_modified_gmt] => 2022-02-11 11:35:27 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4139 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [49] => WP_Post Object ( [ID] => 4138 [post_author] => 5 [post_date] => 2022-01-31 14:09:33 [post_date_gmt] => 2022-01-31 14:09:33 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-31 14:09:33 [post_modified_gmt] => 2022-01-31 14:09:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4138 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [50] => WP_Post Object ( [ID] => 4137 [post_author] => 5 [post_date] => 2022-01-31 13:53:37 [post_date_gmt] => 2022-01-31 13:53:37 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-31 13:54:45 [post_modified_gmt] => 2022-01-31 13:54:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4137 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [51] => WP_Post Object ( [ID] => 4136 [post_author] => 5 [post_date] => 2022-01-31 13:42:47 [post_date_gmt] => 2022-01-31 13:42:47 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-01-31 13:42:47 [post_modified_gmt] => 2022-01-31 13:42:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4136 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [52] => WP_Post Object ( [ID] => 4135 [post_author] => 5 [post_date] => 2022-01-31 13:25:08 [post_date_gmt] => 2022-01-31 13:25:08 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-31 13:25:08 [post_modified_gmt] => 2022-01-31 13:25:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4135 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [53] => WP_Post Object ( [ID] => 4134 [post_author] => 5 [post_date] => 2022-01-31 12:56:28 [post_date_gmt] => 2022-01-31 12:56:28 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-01-31 12:56:28 [post_modified_gmt] => 2022-01-31 12:56:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4134 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [54] => WP_Post Object ( [ID] => 4133 [post_author] => 5 [post_date] => 2022-01-31 12:22:56 [post_date_gmt] => 2022-01-31 12:22:56 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-01-31 12:24:36 [post_modified_gmt] => 2022-01-31 12:24:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4133 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [55] => WP_Post Object ( [ID] => 4131 [post_author] => 5 [post_date] => 2022-01-29 16:21:19 [post_date_gmt] => 2022-01-29 16:21:19 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-01-29 16:31:13 [post_modified_gmt] => 2022-01-29 16:31:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4131 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [56] => WP_Post Object ( [ID] => 4130 [post_author] => 5 [post_date] => 2022-01-29 15:34:50 [post_date_gmt] => 2022-01-29 15:34:50 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-29 15:49:57 [post_modified_gmt] => 2022-01-29 15:49:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4130 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [57] => WP_Post Object ( [ID] => 4129 [post_author] => 5 [post_date] => 2022-01-28 14:43:06 [post_date_gmt] => 2022-01-28 14:43:06 [post_content] => [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-31 16:21:05 [post_modified_gmt] => 2022-03-31 16:21:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4129 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [58] => WP_Post Object ( [ID] => 4128 [post_author] => 5 [post_date] => 2022-01-28 13:38:44 [post_date_gmt] => 2022-01-28 13:38:44 [post_content] => [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-dynavax-covid-19-material-reservation-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-28 13:45:11 [post_modified_gmt] => 2022-01-28 13:45:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4128 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [59] => WP_Post Object ( [ID] => 4058 [post_author] => 5 [post_date] => 2022-01-04 14:25:52 [post_date_gmt] => 2022-01-04 14:25:52 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-04 14:25:52 [post_modified_gmt] => 2022-01-04 14:25:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4058 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [60] => WP_Post Object ( [ID] => 4054 [post_author] => 5 [post_date] => 2022-01-03 11:45:52 [post_date_gmt] => 2022-01-03 11:45:52 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20 [to_ping] => [pinged] => [post_modified] => 2022-01-03 11:46:09 [post_modified_gmt] => 2022-01-03 11:46:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4054 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [61] => WP_Post Object ( [ID] => 4051 [post_author] => 5 [post_date] => 2022-01-03 11:01:41 [post_date_gmt] => 2022-01-03 11:01:41 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-03-09 10:37:08 [post_modified_gmt] => 2022-03-09 10:37:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4051 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [62] => WP_Post Object ( [ID] => 4050 [post_author] => 5 [post_date] => 2022-01-03 10:49:32 [post_date_gmt] => 2022-01-03 10:49:32 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-01-03 10:56:55 [post_modified_gmt] => 2022-01-03 10:56:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4050 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [63] => WP_Post Object ( [ID] => 4047 [post_author] => 5 [post_date] => 2021-12-27 17:17:36 [post_date_gmt] => 2021-12-27 17:17:36 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-01-03 10:43:10 [post_modified_gmt] => 2022-01-03 10:43:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4047 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [64] => WP_Post Object ( [ID] => 4046 [post_author] => 5 [post_date] => 2021-12-27 17:10:47 [post_date_gmt] => 2021-12-27 17:10:47 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14 [to_ping] => [pinged] => [post_modified] => 2021-12-27 17:10:47 [post_modified_gmt] => 2021-12-27 17:10:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4046 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [65] => WP_Post Object ( [ID] => 4045 [post_author] => 5 [post_date] => 2021-12-27 17:07:25 [post_date_gmt] => 2021-12-27 17:07:25 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13 [to_ping] => [pinged] => [post_modified] => 2021-12-27 17:07:25 [post_modified_gmt] => 2021-12-27 17:07:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4045 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [66] => WP_Post Object ( [ID] => 4043 [post_author] => 5 [post_date] => 2021-12-27 16:47:54 [post_date_gmt] => 2021-12-27 16:47:54 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-12-27 16:47:54 [post_modified_gmt] => 2021-12-27 16:47:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4043 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [67] => WP_Post Object ( [ID] => 4042 [post_author] => 5 [post_date] => 2021-12-27 16:41:56 [post_date_gmt] => 2021-12-27 16:41:56 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-27 10:56:31 [post_modified_gmt] => 2022-01-27 10:56:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4042 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [68] => WP_Post Object ( [ID] => 4041 [post_author] => 5 [post_date] => 2021-12-27 16:28:21 [post_date_gmt] => 2021-12-27 16:28:21 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9 [to_ping] => [pinged] => [post_modified] => 2021-12-27 16:28:42 [post_modified_gmt] => 2021-12-27 16:28:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4041 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [69] => WP_Post Object ( [ID] => 4040 [post_author] => 5 [post_date] => 2021-12-27 15:24:04 [post_date_gmt] => 2021-12-27 15:24:04 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-14 12:58:21 [post_modified_gmt] => 2022-03-14 12:58:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4040 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [70] => WP_Post Object ( [ID] => 4038 [post_author] => 5 [post_date] => 2021-12-27 15:08:30 [post_date_gmt] => 2021-12-27 15:08:30 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-24 12:22:28 [post_modified_gmt] => 2022-01-24 12:22:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4038 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [71] => WP_Post Object ( [ID] => 4036 [post_author] => 5 [post_date] => 2021-12-26 17:01:45 [post_date_gmt] => 2021-12-26 17:01:45 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:22:53 [post_modified_gmt] => 2022-02-11 13:22:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4036 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [72] => WP_Post Object ( [ID] => 4035 [post_author] => 5 [post_date] => 2021-12-26 16:47:36 [post_date_gmt] => 2021-12-26 16:47:36 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-12-26 16:47:36 [post_modified_gmt] => 2021-12-26 16:47:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4035 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [73] => WP_Post Object ( [ID] => 4032 [post_author] => 5 [post_date] => 2021-12-26 16:32:27 [post_date_gmt] => 2021-12-26 16:32:27 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-22 14:37:29 [post_modified_gmt] => 2022-01-22 14:37:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4032 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [74] => WP_Post Object ( [ID] => 4029 [post_author] => 5 [post_date] => 2021-12-21 12:22:08 [post_date_gmt] => 2021-12-21 12:22:08 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-24 12:10:58 [post_modified_gmt] => 2022-01-24 12:10:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4029 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [75] => WP_Post Object ( [ID] => 4028 [post_author] => 5 [post_date] => 2021-12-21 11:55:28 [post_date_gmt] => 2021-12-21 11:55:28 [post_content] => [post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-21 11:56:51 [post_modified_gmt] => 2021-12-21 11:56:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4028 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [76] => WP_Post Object ( [ID] => 4024 [post_author] => 5 [post_date] => 2021-12-15 15:33:17 [post_date_gmt] => 2021-12-15 15:33:17 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22 [to_ping] => [pinged] => [post_modified] => 2021-12-15 15:33:17 [post_modified_gmt] => 2021-12-15 15:33:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4024 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [77] => WP_Post Object ( [ID] => 4022 [post_author] => 5 [post_date] => 2021-12-15 14:49:36 [post_date_gmt] => 2021-12-15 14:49:36 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20 [to_ping] => [pinged] => [post_modified] => 2021-12-15 14:51:23 [post_modified_gmt] => 2021-12-15 14:51:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4022 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [78] => WP_Post Object ( [ID] => 4021 [post_author] => 5 [post_date] => 2021-12-15 14:31:00 [post_date_gmt] => 2021-12-15 14:31:00 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19 [to_ping] => [pinged] => [post_modified] => 2021-12-15 14:31:00 [post_modified_gmt] => 2021-12-15 14:31:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4021 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [79] => WP_Post Object ( [ID] => 4020 [post_author] => 5 [post_date] => 2021-12-15 14:24:47 [post_date_gmt] => 2021-12-15 14:24:47 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18 [to_ping] => [pinged] => [post_modified] => 2021-12-15 14:24:47 [post_modified_gmt] => 2021-12-15 14:24:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4020 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [80] => WP_Post Object ( [ID] => 4017 [post_author] => 5 [post_date] => 2021-12-15 13:22:49 [post_date_gmt] => 2021-12-15 13:22:49 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2021-12-15 13:22:49 [post_modified_gmt] => 2021-12-15 13:22:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4017 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [81] => WP_Post Object ( [ID] => 4016 [post_author] => 5 [post_date] => 2021-12-15 13:20:07 [post_date_gmt] => 2021-12-15 13:20:07 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:34:02 [post_modified_gmt] => 2022-01-27 11:34:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4016 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [82] => WP_Post Object ( [ID] => 4014 [post_author] => 5 [post_date] => 2021-12-15 12:33:09 [post_date_gmt] => 2021-12-15 12:33:09 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2021-12-15 12:33:09 [post_modified_gmt] => 2021-12-15 12:33:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4014 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [83] => WP_Post Object ( [ID] => 4013 [post_author] => 5 [post_date] => 2021-12-15 12:16:20 [post_date_gmt] => 2021-12-15 12:16:20 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2021-12-15 12:17:01 [post_modified_gmt] => 2021-12-15 12:17:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4013 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [84] => WP_Post Object ( [ID] => 4012 [post_author] => 5 [post_date] => 2021-12-15 12:01:13 [post_date_gmt] => 2021-12-15 12:01:13 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-12-15 12:01:13 [post_modified_gmt] => 2021-12-15 12:01:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4012 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [85] => WP_Post Object ( [ID] => 4011 [post_author] => 5 [post_date] => 2021-12-14 15:21:54 [post_date_gmt] => 2021-12-14 15:21:54 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2021-12-15 11:48:20 [post_modified_gmt] => 2021-12-15 11:48:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4011 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [86] => WP_Post Object ( [ID] => 4009 [post_author] => 5 [post_date] => 2021-12-14 15:10:51 [post_date_gmt] => 2021-12-14 15:10:51 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-and-gsk-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-09 11:00:07 [post_modified_gmt] => 2022-03-09 11:00:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4009 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [87] => WP_Post Object ( [ID] => 4007 [post_author] => 5 [post_date] => 2021-12-14 08:51:32 [post_date_gmt] => 2021-12-14 08:51:32 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-12-14 08:51:44 [post_modified_gmt] => 2021-12-14 08:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4007 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [88] => WP_Post Object ( [ID] => 4006 [post_author] => 5 [post_date] => 2021-12-14 08:16:01 [post_date_gmt] => 2021-12-14 08:16:01 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-23 14:46:11 [post_modified_gmt] => 2022-03-23 14:46:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4006 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [89] => WP_Post Object ( [ID] => 4004 [post_author] => 5 [post_date] => 2021-12-14 07:57:41 [post_date_gmt] => 2021-12-14 07:57:41 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-12-14 07:57:41 [post_modified_gmt] => 2021-12-14 07:57:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4004 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [90] => WP_Post Object ( [ID] => 4003 [post_author] => 5 [post_date] => 2021-12-13 18:36:53 [post_date_gmt] => 2021-12-13 18:36:53 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:25:43 [post_modified_gmt] => 2022-02-11 13:25:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4003 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [91] => WP_Post Object ( [ID] => 4002 [post_author] => 5 [post_date] => 2021-12-13 18:28:05 [post_date_gmt] => 2021-12-13 18:28:05 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2021-12-13 18:41:28 [post_modified_gmt] => 2021-12-13 18:41:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4002 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [92] => WP_Post Object ( [ID] => 4001 [post_author] => 5 [post_date] => 2021-12-13 14:55:46 [post_date_gmt] => 2021-12-13 14:55:46 [post_content] => [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2021-12-13 18:30:22 [post_modified_gmt] => 2021-12-13 18:30:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=4001 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [93] => WP_Post Object ( [ID] => 3997 [post_author] => 5 [post_date] => 2021-12-13 14:24:49 [post_date_gmt] => 2021-12-13 14:24:49 [post_content] => [post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-13 14:24:59 [post_modified_gmt] => 2021-12-13 14:24:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3997 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [94] => WP_Post Object ( [ID] => 3909 [post_author] => 5 [post_date] => 2021-11-22 13:29:28 [post_date_gmt] => 2021-11-22 13:29:28 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-03-09 11:13:09 [post_modified_gmt] => 2022-03-09 11:13:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3909 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [95] => WP_Post Object ( [ID] => 3908 [post_author] => 5 [post_date] => 2021-11-22 13:20:09 [post_date_gmt] => 2021-11-22 13:20:09 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:28:33 [post_modified_gmt] => 2022-02-11 13:28:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3908 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [96] => WP_Post Object ( [ID] => 3906 [post_author] => 5 [post_date] => 2021-11-22 12:57:50 [post_date_gmt] => 2021-11-22 12:57:50 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:22:44 [post_modified_gmt] => 2022-01-31 15:22:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3906 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [97] => WP_Post Object ( [ID] => 3904 [post_author] => 5 [post_date] => 2021-11-22 12:20:20 [post_date_gmt] => 2021-11-22 12:20:20 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:00 [post_modified_gmt] => 2022-01-31 15:23:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3904 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [98] => WP_Post Object ( [ID] => 3903 [post_author] => 5 [post_date] => 2021-11-22 12:04:07 [post_date_gmt] => 2021-11-22 12:04:07 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:16 [post_modified_gmt] => 2022-01-31 15:23:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3903 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [99] => WP_Post Object ( [ID] => 3901 [post_author] => 5 [post_date] => 2021-11-22 11:42:55 [post_date_gmt] => 2021-11-22 11:42:55 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:34 [post_modified_gmt] => 2022-01-31 15:23:34 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3901 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [100] => WP_Post Object ( [ID] => 3900 [post_author] => 5 [post_date] => 2021-11-22 11:35:10 [post_date_gmt] => 2021-11-22 11:35:10 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:23:52 [post_modified_gmt] => 2022-01-31 15:23:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3900 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [101] => WP_Post Object ( [ID] => 3899 [post_author] => 5 [post_date] => 2021-11-22 11:24:36 [post_date_gmt] => 2021-11-22 11:24:36 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-21 13:42:51 [post_modified_gmt] => 2022-03-21 13:42:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3899 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [102] => WP_Post Object ( [ID] => 3898 [post_author] => 5 [post_date] => 2021-11-22 11:02:44 [post_date_gmt] => 2021-11-22 11:02:44 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:24:53 [post_modified_gmt] => 2022-01-31 15:24:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3898 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [103] => WP_Post Object ( [ID] => 3897 [post_author] => 5 [post_date] => 2021-11-22 10:34:34 [post_date_gmt] => 2021-11-22 10:34:34 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:25:11 [post_modified_gmt] => 2022-01-31 15:25:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3897 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [104] => WP_Post Object ( [ID] => 3896 [post_author] => 5 [post_date] => 2021-11-22 10:27:28 [post_date_gmt] => 2021-11-22 10:27:28 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:25:40 [post_modified_gmt] => 2022-01-31 15:25:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3896 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [105] => WP_Post Object ( [ID] => 3895 [post_author] => 5 [post_date] => 2021-11-22 10:20:20 [post_date_gmt] => 2021-11-22 10:20:20 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-01 09:51:43 [post_modified_gmt] => 2022-04-01 09:51:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3895 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [106] => WP_Post Object ( [ID] => 3892 [post_author] => 5 [post_date] => 2021-11-19 13:53:26 [post_date_gmt] => 2021-11-19 13:53:26 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:26:44 [post_modified_gmt] => 2022-01-31 15:26:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [107] => WP_Post Object ( [ID] => 3891 [post_author] => 5 [post_date] => 2021-11-19 13:11:12 [post_date_gmt] => 2021-11-19 13:11:12 [post_content] => [post_title] => MSD – MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:27:01 [post_modified_gmt] => 2022-01-31 15:27:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3891 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [108] => WP_Post Object ( [ID] => 3890 [post_author] => 5 [post_date] => 2021-11-19 13:00:24 [post_date_gmt] => 2021-11-19 13:00:24 [post_content] => [post_title] => MSD - MPP, Molnupiravir License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => msd-mpp-molnupiravir-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-31 15:27:21 [post_modified_gmt] => 2022-01-31 15:27:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [109] => WP_Post Object ( [ID] => 3869 [post_author] => 5 [post_date] => 2021-11-19 12:55:06 [post_date_gmt] => 2021-11-19 12:55:06 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17 [to_ping] => [pinged] => [post_modified] => 2021-12-02 15:02:14 [post_modified_gmt] => 2021-12-02 15:02:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3869 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [110] => WP_Post Object ( [ID] => 3886 [post_author] => 5 [post_date] => 2021-11-18 16:36:37 [post_date_gmt] => 2021-11-18 16:36:37 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-04-12 06:09:26 [post_modified_gmt] => 2022-04-12 06:09:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3886 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [111] => WP_Post Object ( [ID] => 3884 [post_author] => 5 [post_date] => 2021-11-18 16:17:51 [post_date_gmt] => 2021-11-18 16:17:51 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-03-09 11:17:21 [post_modified_gmt] => 2022-03-09 11:17:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3884 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [112] => WP_Post Object ( [ID] => 3883 [post_author] => 5 [post_date] => 2021-11-18 16:10:24 [post_date_gmt] => 2021-11-18 16:10:24 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13 [to_ping] => [pinged] => [post_modified] => 2021-12-03 12:48:26 [post_modified_gmt] => 2021-12-03 12:48:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3883 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [113] => WP_Post Object ( [ID] => 3882 [post_author] => 5 [post_date] => 2021-11-18 16:01:06 [post_date_gmt] => 2021-11-18 16:01:06 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12 [to_ping] => [pinged] => [post_modified] => 2021-12-03 12:49:07 [post_modified_gmt] => 2021-12-03 12:49:07 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3882 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [114] => WP_Post Object ( [ID] => 3881 [post_author] => 5 [post_date] => 2021-11-18 15:52:45 [post_date_gmt] => 2021-11-18 15:52:45 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-11-18 15:52:45 [post_modified_gmt] => 2021-11-18 15:52:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3881 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [115] => WP_Post Object ( [ID] => 3880 [post_author] => 5 [post_date] => 2021-11-18 15:50:26 [post_date_gmt] => 2021-11-18 15:50:26 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10 [to_ping] => [pinged] => [post_modified] => 2021-11-18 15:50:26 [post_modified_gmt] => 2021-11-18 15:50:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3880 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [116] => WP_Post Object ( [ID] => 3878 [post_author] => 5 [post_date] => 2021-11-18 15:08:19 [post_date_gmt] => 2021-11-18 15:08:19 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-11-18 15:08:19 [post_modified_gmt] => 2021-11-18 15:08:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3878 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [117] => WP_Post Object ( [ID] => 3877 [post_author] => 5 [post_date] => 2021-11-18 15:05:16 [post_date_gmt] => 2021-11-18 15:05:16 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:39:09 [post_modified_gmt] => 2022-01-27 11:39:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3877 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [118] => WP_Post Object ( [ID] => 3876 [post_author] => 5 [post_date] => 2021-11-18 14:51:40 [post_date_gmt] => 2021-11-18 14:51:40 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-11-18 14:51:40 [post_modified_gmt] => 2021-11-18 14:51:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3876 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [119] => WP_Post Object ( [ID] => 3875 [post_author] => 5 [post_date] => 2021-11-18 14:43:39 [post_date_gmt] => 2021-11-18 14:43:39 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-11-22 10:50:23 [post_modified_gmt] => 2021-11-22 10:50:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3875 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [120] => WP_Post Object ( [ID] => 3874 [post_author] => 5 [post_date] => 2021-11-18 14:29:06 [post_date_gmt] => 2021-11-18 14:29:06 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-12 08:08:10 [post_modified_gmt] => 2022-04-12 08:08:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3874 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [121] => WP_Post Object ( [ID] => 3873 [post_author] => 5 [post_date] => 2021-11-18 14:05:12 [post_date_gmt] => 2021-11-18 14:05:12 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-11-19 12:22:45 [post_modified_gmt] => 2021-11-19 12:22:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3873 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [122] => WP_Post Object ( [ID] => 3870 [post_author] => 5 [post_date] => 2021-11-18 12:58:35 [post_date_gmt] => 2021-11-18 12:58:35 [post_content] => [post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement [to_ping] => [pinged] => [post_modified] => 2021-11-19 12:25:29 [post_modified_gmt] => 2021-11-19 12:25:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3870 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [123] => WP_Post Object ( [ID] => 3863 [post_author] => 5 [post_date] => 2021-11-05 14:19:38 [post_date_gmt] => 2021-11-05 14:19:38 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:22:42 [post_modified_gmt] => 2022-04-18 09:22:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3863 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [124] => WP_Post Object ( [ID] => 3861 [post_author] => 5 [post_date] => 2021-11-05 13:59:54 [post_date_gmt] => 2021-11-05 13:59:54 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:16:26 [post_modified_gmt] => 2022-04-18 07:16:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3861 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [125] => WP_Post Object ( [ID] => 3860 [post_author] => 5 [post_date] => 2021-11-05 13:51:48 [post_date_gmt] => 2021-11-05 13:51:48 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:16:48 [post_modified_gmt] => 2022-04-18 07:16:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3860 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [126] => WP_Post Object ( [ID] => 3859 [post_author] => 5 [post_date] => 2021-11-05 13:44:47 [post_date_gmt] => 2021-11-05 13:44:47 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:28:57 [post_modified_gmt] => 2022-04-18 07:28:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3859 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [127] => WP_Post Object ( [ID] => 3858 [post_author] => 5 [post_date] => 2021-11-05 13:39:37 [post_date_gmt] => 2021-11-05 13:39:37 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:54:11 [post_modified_gmt] => 2022-04-18 07:54:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3858 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [128] => WP_Post Object ( [ID] => 3857 [post_author] => 5 [post_date] => 2021-11-05 13:37:12 [post_date_gmt] => 2021-11-05 13:37:12 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-18 07:41:41 [post_modified_gmt] => 2022-04-18 07:41:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3857 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [129] => WP_Post Object ( [ID] => 3856 [post_author] => 5 [post_date] => 2021-11-05 13:12:38 [post_date_gmt] => 2021-11-05 13:12:38 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:11:42 [post_modified_gmt] => 2022-04-18 08:11:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3856 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [130] => WP_Post Object ( [ID] => 3855 [post_author] => 5 [post_date] => 2021-11-05 13:10:25 [post_date_gmt] => 2021-11-05 13:10:25 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:05:19 [post_modified_gmt] => 2022-04-18 08:05:19 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3855 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [131] => WP_Post Object ( [ID] => 3854 [post_author] => 5 [post_date] => 2021-11-05 13:03:41 [post_date_gmt] => 2021-11-05 13:03:41 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:15:00 [post_modified_gmt] => 2022-04-18 08:15:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3854 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [132] => WP_Post Object ( [ID] => 3852 [post_author] => 5 [post_date] => 2021-11-05 12:43:57 [post_date_gmt] => 2021-11-05 12:43:57 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:33:20 [post_modified_gmt] => 2022-04-18 08:33:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3852 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [133] => WP_Post Object ( [ID] => 3851 [post_author] => 5 [post_date] => 2021-11-05 12:41:54 [post_date_gmt] => 2021-11-05 12:41:54 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:45:20 [post_modified_gmt] => 2022-04-18 08:45:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3851 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [134] => WP_Post Object ( [ID] => 3849 [post_author] => 5 [post_date] => 2021-11-05 12:30:09 [post_date_gmt] => 2021-11-05 12:30:09 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:52:12 [post_modified_gmt] => 2022-04-18 08:52:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3849 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [135] => WP_Post Object ( [ID] => 3848 [post_author] => 5 [post_date] => 2021-11-05 12:27:44 [post_date_gmt] => 2021-11-05 12:27:44 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-18 08:58:14 [post_modified_gmt] => 2022-04-18 08:58:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3848 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [136] => WP_Post Object ( [ID] => 3847 [post_author] => 5 [post_date] => 2021-11-05 12:25:40 [post_date_gmt] => 2021-11-05 12:25:40 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:07:16 [post_modified_gmt] => 2022-04-18 09:07:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3847 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [137] => WP_Post Object ( [ID] => 3846 [post_author] => 5 [post_date] => 2021-11-05 12:14:17 [post_date_gmt] => 2021-11-05 12:14:17 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:08:02 [post_modified_gmt] => 2022-04-18 09:08:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3846 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [138] => WP_Post Object ( [ID] => 3845 [post_author] => 5 [post_date] => 2021-11-05 11:56:34 [post_date_gmt] => 2021-11-05 11:56:34 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:20:20 [post_modified_gmt] => 2022-04-18 09:20:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3845 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [139] => WP_Post Object ( [ID] => 3819 [post_author] => 6 [post_date] => 2021-09-15 12:17:55 [post_date_gmt] => 2021-09-15 12:17:55 [post_content] => [post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-and-gsk-collaboration-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-15 11:45:22 [post_modified_gmt] => 2021-12-15 11:45:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3819 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [140] => WP_Post Object ( [ID] => 3812 [post_author] => 5 [post_date] => 2021-09-10 12:44:57 [post_date_gmt] => 2021-09-10 12:44:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17 [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:13:50 [post_modified_gmt] => 2022-04-20 09:13:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3812 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [141] => WP_Post Object ( [ID] => 3810 [post_author] => 5 [post_date] => 2021-09-10 12:21:33 [post_date_gmt] => 2021-09-10 12:21:33 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:11:54 [post_modified_gmt] => 2022-04-20 07:11:54 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3810 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [142] => WP_Post Object ( [ID] => 3809 [post_author] => 5 [post_date] => 2021-09-10 12:11:12 [post_date_gmt] => 2021-09-10 12:11:12 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:19:45 [post_modified_gmt] => 2022-04-20 09:19:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3809 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [143] => WP_Post Object ( [ID] => 3808 [post_author] => 5 [post_date] => 2021-09-10 11:59:11 [post_date_gmt] => 2021-09-10 11:59:11 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:24:05 [post_modified_gmt] => 2022-04-20 07:24:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3808 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [144] => WP_Post Object ( [ID] => 3807 [post_author] => 5 [post_date] => 2021-09-10 11:55:25 [post_date_gmt] => 2021-09-10 11:55:25 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:42:12 [post_modified_gmt] => 2022-04-20 07:42:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3807 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [145] => WP_Post Object ( [ID] => 3806 [post_author] => 5 [post_date] => 2021-09-10 11:47:18 [post_date_gmt] => 2021-09-10 11:47:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:16:48 [post_modified_gmt] => 2022-04-20 09:16:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3806 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [146] => WP_Post Object ( [ID] => 3805 [post_author] => 5 [post_date] => 2021-09-10 11:33:53 [post_date_gmt] => 2021-09-10 11:33:53 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:46:59 [post_modified_gmt] => 2022-04-20 07:46:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3805 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [147] => WP_Post Object ( [ID] => 3804 [post_author] => 5 [post_date] => 2021-09-10 11:20:59 [post_date_gmt] => 2021-09-10 11:20:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:50:11 [post_modified_gmt] => 2022-04-20 07:50:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3804 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [148] => WP_Post Object ( [ID] => 3803 [post_author] => 5 [post_date] => 2021-09-10 10:54:42 [post_date_gmt] => 2021-09-10 10:54:42 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:51:06 [post_modified_gmt] => 2022-04-20 07:51:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3803 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [149] => WP_Post Object ( [ID] => 3802 [post_author] => 5 [post_date] => 2021-09-10 10:45:57 [post_date_gmt] => 2021-09-10 10:45:57 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-04-20 07:54:14 [post_modified_gmt] => 2022-04-20 07:54:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3802 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [150] => WP_Post Object ( [ID] => 3801 [post_author] => 5 [post_date] => 2021-09-10 10:36:30 [post_date_gmt] => 2021-09-10 10:36:30 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:05:17 [post_modified_gmt] => 2022-04-20 08:05:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3801 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [151] => WP_Post Object ( [ID] => 3800 [post_author] => 5 [post_date] => 2021-09-10 10:25:59 [post_date_gmt] => 2021-09-10 10:25:59 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:35:52 [post_modified_gmt] => 2022-04-20 08:35:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3800 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [152] => WP_Post Object ( [ID] => 3799 [post_author] => 5 [post_date] => 2021-09-10 10:07:18 [post_date_gmt] => 2021-09-10 10:07:18 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:44:40 [post_modified_gmt] => 2022-04-20 08:44:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3799 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [153] => WP_Post Object ( [ID] => 3798 [post_author] => 5 [post_date] => 2021-09-10 10:02:07 [post_date_gmt] => 2021-09-10 10:02:07 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:46:03 [post_modified_gmt] => 2022-04-20 08:46:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3798 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [154] => WP_Post Object ( [ID] => 3797 [post_author] => 5 [post_date] => 2021-09-10 09:54:44 [post_date_gmt] => 2021-09-10 09:54:44 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-20 08:53:13 [post_modified_gmt] => 2022-04-20 08:53:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3797 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [155] => WP_Post Object ( [ID] => 3796 [post_author] => 5 [post_date] => 2021-09-10 09:03:43 [post_date_gmt] => 2021-09-10 09:03:43 [post_content] => [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-20 09:07:03 [post_modified_gmt] => 2022-04-20 09:07:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3796 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [156] => WP_Post Object ( [ID] => 3792 [post_author] => 5 [post_date] => 2021-09-09 14:23:13 [post_date_gmt] => 2021-09-09 14:23:13 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 12:44:33 [post_modified_gmt] => 2022-03-09 12:44:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3792 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [157] => WP_Post Object ( [ID] => 3791 [post_author] => 5 [post_date] => 2021-09-09 14:18:44 [post_date_gmt] => 2021-09-09 14:18:44 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:00:35 [post_modified_gmt] => 2021-11-04 09:00:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3791 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [158] => WP_Post Object ( [ID] => 3789 [post_author] => 5 [post_date] => 2021-09-09 14:07:30 [post_date_gmt] => 2021-09-09 14:07:30 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:42:42 [post_modified_gmt] => 2022-01-27 11:42:42 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3789 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [159] => WP_Post Object ( [ID] => 3788 [post_author] => 5 [post_date] => 2021-09-09 14:00:40 [post_date_gmt] => 2021-09-09 14:00:40 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:02:12 [post_modified_gmt] => 2021-11-04 09:02:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3788 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [160] => WP_Post Object ( [ID] => 3786 [post_author] => 5 [post_date] => 2021-09-09 13:20:21 [post_date_gmt] => 2021-09-09 13:20:21 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-21 13:55:09 [post_modified_gmt] => 2022-03-21 13:55:09 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3786 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [161] => WP_Post Object ( [ID] => 3785 [post_author] => 5 [post_date] => 2021-09-09 13:10:11 [post_date_gmt] => 2021-09-09 13:10:11 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:04:36 [post_modified_gmt] => 2021-11-04 09:04:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3785 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [162] => WP_Post Object ( [ID] => 3784 [post_author] => 5 [post_date] => 2021-09-09 13:03:52 [post_date_gmt] => 2021-09-09 13:03:52 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:05:12 [post_modified_gmt] => 2021-11-04 09:05:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3784 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [163] => WP_Post Object ( [ID] => 3783 [post_author] => 5 [post_date] => 2021-09-09 12:41:47 [post_date_gmt] => 2021-09-09 12:41:47 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-11-04 09:05:50 [post_modified_gmt] => 2021-11-04 09:05:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3783 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [164] => WP_Post Object ( [ID] => 3782 [post_author] => 5 [post_date] => 2021-09-09 12:36:36 [post_date_gmt] => 2021-09-09 12:36:36 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:50:50 [post_modified_gmt] => 2022-03-28 10:50:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3782 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [165] => WP_Post Object ( [ID] => 3781 [post_author] => 5 [post_date] => 2021-09-09 12:29:54 [post_date_gmt] => 2021-09-09 12:29:54 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:18:43 [post_modified_gmt] => 2021-11-23 14:18:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3781 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [166] => WP_Post Object ( [ID] => 3778 [post_author] => 5 [post_date] => 2021-09-09 11:52:53 [post_date_gmt] => 2021-09-09 11:52:53 [post_content] => [post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-06 12:35:12 [post_modified_gmt] => 2021-12-06 12:35:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3778 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [167] => WP_Post Object ( [ID] => 3769 [post_author] => 5 [post_date] => 2021-09-02 14:55:06 [post_date_gmt] => 2021-09-02 14:55:06 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => us-department-of-defense-novavax-covid-19-vaccine-development-agreement [to_ping] => [pinged] => [post_modified] => 2021-12-02 15:00:21 [post_modified_gmt] => 2021-12-02 15:00:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3769 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [168] => WP_Post Object ( [ID] => 3768 [post_author] => 5 [post_date] => 2021-09-02 14:27:00 [post_date_gmt] => 2021-09-02 14:27:00 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-12-03 14:19:56 [post_modified_gmt] => 2021-12-03 14:19:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3768 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [169] => WP_Post Object ( [ID] => 3765 [post_author] => 5 [post_date] => 2021-09-01 14:09:03 [post_date_gmt] => 2021-09-01 14:09:03 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:49:00 [post_modified_gmt] => 2022-03-28 10:49:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3765 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [170] => WP_Post Object ( [ID] => 3764 [post_author] => 5 [post_date] => 2021-09-01 12:17:32 [post_date_gmt] => 2021-09-01 12:17:32 [post_content] => [post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => barda-moderna-covid-19-vaccine-development-agreement-3 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:15:32 [post_modified_gmt] => 2021-11-23 14:15:32 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3764 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [171] => WP_Post Object ( [ID] => 3758 [post_author] => 5 [post_date] => 2021-08-26 12:04:03 [post_date_gmt] => 2021-08-26 12:04:03 [post_content] => [post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => barda-moderna-covid-19-vaccine-development-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:43:14 [post_modified_gmt] => 2022-03-28 10:43:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3758 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [172] => WP_Post Object ( [ID] => 3741 [post_author] => 5 [post_date] => 2021-08-24 09:13:39 [post_date_gmt] => 2021-08-24 09:13:39 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-04 12:32:22 [post_modified_gmt] => 2022-01-04 12:32:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3741 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [173] => WP_Post Object ( [ID] => 3696 [post_author] => 5 [post_date] => 2021-08-19 14:23:22 [post_date_gmt] => 2021-08-19 14:23:22 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:37:29 [post_modified_gmt] => 2022-01-18 12:37:29 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3696 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [174] => WP_Post Object ( [ID] => 3495 [post_author] => 5 [post_date] => 2021-08-10 13:06:45 [post_date_gmt] => 2021-08-10 13:06:45 [post_content] => [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => dod-moderna-covid-19-vaccine-supply-agreement [to_ping] => [pinged] => [post_modified] => 2021-11-29 14:12:04 [post_modified_gmt] => 2021-11-29 14:12:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3495 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [175] => WP_Post Object ( [ID] => 3493 [post_author] => 5 [post_date] => 2021-08-10 11:15:39 [post_date_gmt] => 2021-08-10 11:15:39 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement [to_ping] => [pinged] => [post_modified] => 2022-02-28 08:24:35 [post_modified_gmt] => 2022-02-28 08:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3493 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [176] => WP_Post Object ( [ID] => 3436 [post_author] => 6 [post_date] => 2021-07-01 03:48:49 [post_date_gmt] => 2021-07-01 03:48:49 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:22:36 [post_modified_gmt] => 2022-04-18 09:22:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3436 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [177] => WP_Post Object ( [ID] => 3434 [post_author] => 6 [post_date] => 2021-07-01 03:44:18 [post_date_gmt] => 2021-07-01 03:44:18 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:28:59 [post_modified_gmt] => 2022-04-18 09:28:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3434 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [178] => WP_Post Object ( [ID] => 3433 [post_author] => 6 [post_date] => 2021-07-01 03:41:21 [post_date_gmt] => 2021-07-01 03:41:21 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:32:11 [post_modified_gmt] => 2022-04-18 09:32:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3433 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [179] => WP_Post Object ( [ID] => 3431 [post_author] => 6 [post_date] => 2021-07-01 03:38:49 [post_date_gmt] => 2021-07-01 03:38:49 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:41:10 [post_modified_gmt] => 2022-04-18 09:41:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3431 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [180] => WP_Post Object ( [ID] => 3430 [post_author] => 6 [post_date] => 2021-07-01 03:27:51 [post_date_gmt] => 2021-07-01 03:27:51 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:45:31 [post_modified_gmt] => 2022-04-18 09:45:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3430 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [181] => WP_Post Object ( [ID] => 3428 [post_author] => 6 [post_date] => 2021-07-01 03:24:00 [post_date_gmt] => 2021-07-01 03:24:00 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:47:22 [post_modified_gmt] => 2022-04-18 09:47:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3428 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [182] => WP_Post Object ( [ID] => 3427 [post_author] => 6 [post_date] => 2021-07-01 03:22:23 [post_date_gmt] => 2021-07-01 03:22:23 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-18 09:49:38 [post_modified_gmt] => 2022-04-18 09:49:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3427 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [183] => WP_Post Object ( [ID] => 3426 [post_author] => 6 [post_date] => 2021-07-01 03:06:23 [post_date_gmt] => 2021-07-01 03:06:23 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:28:05 [post_modified_gmt] => 2022-04-18 10:28:05 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3426 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [184] => WP_Post Object ( [ID] => 3424 [post_author] => 6 [post_date] => 2021-07-01 03:03:57 [post_date_gmt] => 2021-07-01 03:03:57 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:47:10 [post_modified_gmt] => 2022-04-18 10:47:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3424 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [185] => WP_Post Object ( [ID] => 3422 [post_author] => 6 [post_date] => 2021-07-01 02:58:21 [post_date_gmt] => 2021-07-01 02:58:21 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:48:25 [post_modified_gmt] => 2022-04-18 10:48:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3422 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [186] => WP_Post Object ( [ID] => 3421 [post_author] => 6 [post_date] => 2021-07-01 02:56:30 [post_date_gmt] => 2021-07-01 02:56:30 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-04-18 10:51:44 [post_modified_gmt] => 2022-04-18 10:51:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3421 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [187] => WP_Post Object ( [ID] => 3420 [post_author] => 6 [post_date] => 2021-07-01 02:52:05 [post_date_gmt] => 2021-07-01 02:52:05 [post_content] => [post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement [to_ping] => [pinged] => [post_modified] => 2022-04-18 11:01:10 [post_modified_gmt] => 2022-04-18 11:01:10 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3420 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [188] => WP_Post Object ( [ID] => 3418 [post_author] => 5 [post_date] => 2021-06-30 19:06:19 [post_date_gmt] => 2021-06-30 19:06:19 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:03:49 [post_modified_gmt] => 2022-03-09 13:03:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3418 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [189] => WP_Post Object ( [ID] => 3417 [post_author] => 5 [post_date] => 2021-06-30 19:04:34 [post_date_gmt] => 2021-06-30 19:04:34 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:12:39 [post_modified_gmt] => 2021-09-01 15:12:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3417 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [190] => WP_Post Object ( [ID] => 3416 [post_author] => 5 [post_date] => 2021-06-30 19:02:19 [post_date_gmt] => 2021-06-30 19:02:19 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:12:57 [post_modified_gmt] => 2021-09-01 15:12:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3416 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [191] => WP_Post Object ( [ID] => 3415 [post_author] => 5 [post_date] => 2021-06-30 19:00:20 [post_date_gmt] => 2021-06-30 19:00:20 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9 [to_ping] => [pinged] => [post_modified] => 2021-11-30 12:40:36 [post_modified_gmt] => 2021-11-30 12:40:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3415 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [192] => WP_Post Object ( [ID] => 3414 [post_author] => 5 [post_date] => 2021-06-30 18:54:43 [post_date_gmt] => 2021-06-30 18:54:43 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:08:59 [post_modified_gmt] => 2021-09-01 15:08:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3414 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [193] => WP_Post Object ( [ID] => 3413 [post_author] => 5 [post_date] => 2021-06-30 18:52:08 [post_date_gmt] => 2021-06-30 18:52:08 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:10:41 [post_modified_gmt] => 2021-09-01 15:10:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3413 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [194] => WP_Post Object ( [ID] => 3412 [post_author] => 5 [post_date] => 2021-06-30 18:48:13 [post_date_gmt] => 2021-06-30 18:48:13 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-02-11 13:32:40 [post_modified_gmt] => 2022-02-11 13:32:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3412 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [195] => WP_Post Object ( [ID] => 3411 [post_author] => 5 [post_date] => 2021-06-30 18:39:53 [post_date_gmt] => 2021-06-30 18:39:53 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:11:28 [post_modified_gmt] => 2021-09-01 15:11:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3411 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [196] => WP_Post Object ( [ID] => 3410 [post_author] => 5 [post_date] => 2021-06-30 18:37:02 [post_date_gmt] => 2021-06-30 18:37:02 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:09:38 [post_modified_gmt] => 2021-09-01 15:09:38 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3410 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [197] => WP_Post Object ( [ID] => 3409 [post_author] => 5 [post_date] => 2021-06-30 18:34:04 [post_date_gmt] => 2021-06-30 18:34:04 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-24 12:58:15 [post_modified_gmt] => 2022-01-24 12:58:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3409 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [198] => WP_Post Object ( [ID] => 3406 [post_author] => 5 [post_date] => 2021-06-30 18:25:58 [post_date_gmt] => 2021-06-30 18:25:58 [post_content] => [post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement [to_ping] => [pinged] => [post_modified] => 2021-09-01 15:11:44 [post_modified_gmt] => 2021-09-01 15:11:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3406 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [199] => WP_Post Object ( [ID] => 3372 [post_author] => 5 [post_date] => 2021-06-30 15:06:19 [post_date_gmt] => 2021-06-30 15:06:19 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:05:39 [post_modified_gmt] => 2022-03-09 13:05:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3372 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [200] => WP_Post Object ( [ID] => 3370 [post_author] => 5 [post_date] => 2021-06-30 15:01:06 [post_date_gmt] => 2021-06-30 15:01:06 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-27 11:51:17 [post_modified_gmt] => 2022-01-27 11:51:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3370 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [201] => WP_Post Object ( [ID] => 3368 [post_author] => 5 [post_date] => 2021-06-30 14:58:39 [post_date_gmt] => 2021-06-30 14:58:39 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9 [to_ping] => [pinged] => [post_modified] => 2021-08-24 08:10:31 [post_modified_gmt] => 2021-08-24 08:10:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3368 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [202] => WP_Post Object ( [ID] => 3366 [post_author] => 5 [post_date] => 2021-06-30 14:53:53 [post_date_gmt] => 2021-06-30 14:53:53 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8 [to_ping] => [pinged] => [post_modified] => 2021-06-30 14:53:53 [post_modified_gmt] => 2021-06-30 14:53:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3366 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [203] => WP_Post Object ( [ID] => 3364 [post_author] => 5 [post_date] => 2021-06-30 14:47:34 [post_date_gmt] => 2021-06-30 14:47:34 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7 [to_ping] => [pinged] => [post_modified] => 2021-09-02 12:46:22 [post_modified_gmt] => 2021-09-02 12:46:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3364 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [204] => WP_Post Object ( [ID] => 3361 [post_author] => 5 [post_date] => 2021-06-30 14:30:51 [post_date_gmt] => 2021-06-30 14:30:51 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-12-03 14:22:31 [post_modified_gmt] => 2021-12-03 14:22:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3361 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [205] => WP_Post Object ( [ID] => 3360 [post_author] => 5 [post_date] => 2021-06-30 14:28:40 [post_date_gmt] => 2021-06-30 14:28:40 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-12-07 11:53:01 [post_modified_gmt] => 2021-12-07 11:53:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3360 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [206] => WP_Post Object ( [ID] => 3356 [post_author] => 5 [post_date] => 2021-06-30 13:53:23 [post_date_gmt] => 2021-06-30 13:53:23 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:44:11 [post_modified_gmt] => 2022-03-28 10:44:11 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3356 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [207] => WP_Post Object ( [ID] => 3354 [post_author] => 5 [post_date] => 2021-06-30 13:29:21 [post_date_gmt] => 2021-06-30 13:29:21 [post_content] => [post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2 [to_ping] => [pinged] => [post_modified] => 2021-06-30 13:29:21 [post_modified_gmt] => 2021-06-30 13:29:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3354 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [208] => WP_Post Object ( [ID] => 3352 [post_author] => 5 [post_date] => 2021-06-30 13:24:49 [post_date_gmt] => 2021-06-30 13:24:49 [post_content] => [post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement [to_ping] => [pinged] => [post_modified] => 2022-03-30 12:46:37 [post_modified_gmt] => 2022-03-30 12:46:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3352 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [209] => WP_Post Object ( [ID] => 3304 [post_author] => 6 [post_date] => 2021-06-30 09:30:56 [post_date_gmt] => 2021-06-30 09:30:56 [post_content] => [post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:01:21 [post_modified_gmt] => 2021-08-23 10:01:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3304 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [210] => WP_Post Object ( [ID] => 3221 [post_author] => 6 [post_date] => 2021-06-28 12:23:49 [post_date_gmt] => 2021-06-28 12:23:49 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:24 [post_modified_gmt] => 2021-08-23 09:51:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3221 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [211] => WP_Post Object ( [ID] => 3220 [post_author] => 6 [post_date] => 2021-06-28 12:22:09 [post_date_gmt] => 2021-06-28 12:22:09 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:08:44 [post_modified_gmt] => 2022-03-09 13:08:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3220 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [212] => WP_Post Object ( [ID] => 3219 [post_author] => 6 [post_date] => 2021-06-28 12:19:29 [post_date_gmt] => 2021-06-28 12:19:29 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:33 [post_modified_gmt] => 2021-08-23 09:51:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3219 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [213] => WP_Post Object ( [ID] => 3218 [post_author] => 6 [post_date] => 2021-06-28 12:16:20 [post_date_gmt] => 2021-06-28 12:16:20 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:37 [post_modified_gmt] => 2021-08-23 09:51:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3218 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [214] => WP_Post Object ( [ID] => 3217 [post_author] => 6 [post_date] => 2021-06-28 12:14:37 [post_date_gmt] => 2021-06-28 12:14:37 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:41 [post_modified_gmt] => 2021-08-23 09:51:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3217 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [215] => WP_Post Object ( [ID] => 3216 [post_author] => 6 [post_date] => 2021-06-28 12:11:22 [post_date_gmt] => 2021-06-28 12:11:22 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:45 [post_modified_gmt] => 2021-08-23 09:51:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3216 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [216] => WP_Post Object ( [ID] => 3215 [post_author] => 6 [post_date] => 2021-06-28 12:07:55 [post_date_gmt] => 2021-06-28 12:07:55 [post_content] => [post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:51:48 [post_modified_gmt] => 2021-08-23 09:51:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3215 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [217] => WP_Post Object ( [ID] => 3127 [post_author] => 6 [post_date] => 2021-06-03 15:08:41 [post_date_gmt] => 2021-06-03 15:08:41 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:52:45 [post_modified_gmt] => 2021-08-23 09:52:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3127 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [218] => WP_Post Object ( [ID] => 3126 [post_author] => 6 [post_date] => 2021-06-03 15:05:40 [post_date_gmt] => 2021-06-03 15:05:40 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:52:49 [post_modified_gmt] => 2021-08-23 09:52:49 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3126 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [219] => WP_Post Object ( [ID] => 3125 [post_author] => 6 [post_date] => 2021-06-03 15:03:17 [post_date_gmt] => 2021-06-03 15:03:17 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:13:17 [post_modified_gmt] => 2022-03-09 13:13:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3125 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [220] => WP_Post Object ( [ID] => 3124 [post_author] => 6 [post_date] => 2021-06-03 15:01:23 [post_date_gmt] => 2021-06-03 15:01:23 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:52:56 [post_modified_gmt] => 2021-08-23 09:52:56 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3124 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [221] => WP_Post Object ( [ID] => 3123 [post_author] => 6 [post_date] => 2021-06-03 14:51:22 [post_date_gmt] => 2021-06-03 14:51:22 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5 [to_ping] => [pinged] => [post_modified] => 2021-11-23 13:12:13 [post_modified_gmt] => 2021-11-23 13:12:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3123 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [222] => WP_Post Object ( [ID] => 3122 [post_author] => 6 [post_date] => 2021-06-03 14:45:44 [post_date_gmt] => 2021-06-03 14:45:44 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4 [to_ping] => [pinged] => [post_modified] => 2021-11-23 15:08:08 [post_modified_gmt] => 2021-11-23 15:08:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3122 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [223] => WP_Post Object ( [ID] => 3121 [post_author] => 6 [post_date] => 2021-06-03 14:26:32 [post_date_gmt] => 2021-06-03 14:26:32 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:53:08 [post_modified_gmt] => 2021-08-23 09:53:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3121 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [224] => WP_Post Object ( [ID] => 3120 [post_author] => 6 [post_date] => 2021-06-03 14:24:03 [post_date_gmt] => 2021-06-03 14:24:03 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2 [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:53:12 [post_modified_gmt] => 2021-08-23 09:53:12 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3120 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [225] => WP_Post Object ( [ID] => 3119 [post_author] => 6 [post_date] => 2021-06-03 14:21:50 [post_date_gmt] => 2021-06-03 14:21:50 [post_content] => [post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => pfizer-biontech-dominican-republic-binding-term-sheet [to_ping] => [pinged] => [post_modified] => 2021-08-23 09:53:15 [post_modified_gmt] => 2021-08-23 09:53:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=3119 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [226] => WP_Post Object ( [ID] => 2956 [post_author] => 6 [post_date] => 2021-05-28 18:56:15 [post_date_gmt] => 2021-05-28 18:56:15 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:06 [post_modified_gmt] => 2021-08-23 10:02:06 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2956 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [227] => WP_Post Object ( [ID] => 2961 [post_author] => 6 [post_date] => 2021-05-28 18:55:47 [post_date_gmt] => 2021-05-28 18:55:47 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11 [to_ping] => [pinged] => [post_modified] => 2021-11-23 12:41:04 [post_modified_gmt] => 2021-11-23 12:41:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2961 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [228] => WP_Post Object ( [ID] => 2965 [post_author] => 6 [post_date] => 2021-05-28 18:55:12 [post_date_gmt] => 2021-05-28 18:55:12 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:15 [post_modified_gmt] => 2021-08-23 10:02:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2965 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [229] => WP_Post Object ( [ID] => 2947 [post_author] => 6 [post_date] => 2021-05-28 18:54:17 [post_date_gmt] => 2021-05-28 18:54:17 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:17 [post_modified_gmt] => 2021-08-23 10:02:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2947 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [230] => WP_Post Object ( [ID] => 2960 [post_author] => 6 [post_date] => 2021-05-28 18:53:36 [post_date_gmt] => 2021-05-28 18:53:36 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:20 [post_modified_gmt] => 2021-08-23 10:02:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2960 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [231] => WP_Post Object ( [ID] => 2964 [post_author] => 6 [post_date] => 2021-05-28 18:53:11 [post_date_gmt] => 2021-05-28 18:53:11 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7 [to_ping] => [pinged] => [post_modified] => 2021-08-23 10:02:24 [post_modified_gmt] => 2021-08-23 10:02:24 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2964 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [232] => WP_Post Object ( [ID] => 2958 [post_author] => 6 [post_date] => 2021-05-28 18:52:54 [post_date_gmt] => 2021-05-28 18:52:54 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6 [to_ping] => [pinged] => [post_modified] => 2021-12-03 10:13:48 [post_modified_gmt] => 2021-12-03 10:13:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2958 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [233] => WP_Post Object ( [ID] => 2949 [post_author] => 6 [post_date] => 2021-05-28 18:52:06 [post_date_gmt] => 2021-05-28 18:52:06 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5 [to_ping] => [pinged] => [post_modified] => 2021-11-23 12:37:55 [post_modified_gmt] => 2021-11-23 12:37:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2949 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [234] => WP_Post Object ( [ID] => 2957 [post_author] => 6 [post_date] => 2021-05-28 18:51:39 [post_date_gmt] => 2021-05-28 18:51:39 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:00:44 [post_modified_gmt] => 2022-01-27 12:00:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2957 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [235] => WP_Post Object ( [ID] => 2962 [post_author] => 6 [post_date] => 2021-05-28 18:50:18 [post_date_gmt] => 2021-05-28 18:50:18 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3 [to_ping] => [pinged] => [post_modified] => 2021-11-23 12:38:17 [post_modified_gmt] => 2021-11-23 12:38:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2962 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [236] => WP_Post Object ( [ID] => 2945 [post_author] => 6 [post_date] => 2021-05-28 14:03:27 [post_date_gmt] => 2021-05-28 14:03:27 [post_content] => [post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222 [to_ping] => [pinged] => [post_modified] => 2021-12-03 10:13:02 [post_modified_gmt] => 2021-12-03 10:13:02 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2945 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [237] => WP_Post Object ( [ID] => 2909 [post_author] => 6 [post_date] => 2021-05-19 15:13:58 [post_date_gmt] => 2021-05-19 15:13:58 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-02-28 08:35:40 [post_modified_gmt] => 2022-02-28 08:35:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2909 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [238] => WP_Post Object ( [ID] => 2908 [post_author] => 6 [post_date] => 2021-05-19 15:08:05 [post_date_gmt] => 2021-05-19 15:08:05 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-02-28 08:59:23 [post_modified_gmt] => 2022-02-28 08:59:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2908 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [239] => WP_Post Object ( [ID] => 2907 [post_author] => 6 [post_date] => 2021-05-19 14:46:20 [post_date_gmt] => 2021-05-19 14:46:20 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-02-28 09:05:23 [post_modified_gmt] => 2022-02-28 09:05:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2907 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [240] => WP_Post Object ( [ID] => 2893 [post_author] => 6 [post_date] => 2021-05-19 14:40:45 [post_date_gmt] => 2021-05-19 14:40:45 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-02-28 09:23:17 [post_modified_gmt] => 2022-02-28 09:23:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2893 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [241] => WP_Post Object ( [ID] => 2892 [post_author] => 6 [post_date] => 2021-05-14 19:30:23 [post_date_gmt] => 2021-05-14 19:30:23 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-04-01 10:11:21 [post_modified_gmt] => 2022-04-01 10:11:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2892 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [242] => WP_Post Object ( [ID] => 2890 [post_author] => 6 [post_date] => 2021-05-14 19:14:07 [post_date_gmt] => 2021-05-14 19:14:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:45:33 [post_modified_gmt] => 2022-03-28 10:45:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2890 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [243] => WP_Post Object ( [ID] => 2889 [post_author] => 6 [post_date] => 2021-05-14 19:09:07 [post_date_gmt] => 2021-05-14 19:09:07 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-02-28 10:58:28 [post_modified_gmt] => 2022-02-28 10:58:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2889 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [244] => WP_Post Object ( [ID] => 2885 [post_author] => 5 [post_date] => 2021-05-14 18:17:37 [post_date_gmt] => 2021-05-14 18:17:37 [post_content] => [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement [to_ping] => [pinged] => [post_modified] => 2022-02-28 14:01:15 [post_modified_gmt] => 2022-02-28 14:01:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2885 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [245] => WP_Post Object ( [ID] => 2873 [post_author] => 6 [post_date] => 2021-05-11 15:17:08 [post_date_gmt] => 2021-05-11 15:17:08 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6 [to_ping] => [pinged] => [post_modified] => 2021-11-22 15:50:47 [post_modified_gmt] => 2021-11-22 15:50:47 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2873 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [246] => WP_Post Object ( [ID] => 2872 [post_author] => 6 [post_date] => 2021-05-11 15:14:24 [post_date_gmt] => 2021-05-11 15:14:24 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5 [to_ping] => [pinged] => [post_modified] => 2021-12-06 12:00:31 [post_modified_gmt] => 2021-12-06 12:00:31 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2872 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [247] => WP_Post Object ( [ID] => 2870 [post_author] => 6 [post_date] => 2021-05-11 15:07:59 [post_date_gmt] => 2021-05-11 15:07:59 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4 [to_ping] => [pinged] => [post_modified] => 2021-06-15 09:15:21 [post_modified_gmt] => 2021-06-15 09:15:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2870 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [248] => WP_Post Object ( [ID] => 2869 [post_author] => 6 [post_date] => 2021-05-11 14:53:04 [post_date_gmt] => 2021-05-11 14:53:04 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3 [to_ping] => [pinged] => [post_modified] => 2021-05-14 09:15:00 [post_modified_gmt] => 2021-05-14 09:15:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2869 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [249] => WP_Post Object ( [ID] => 2867 [post_author] => 6 [post_date] => 2021-05-11 14:28:02 [post_date_gmt] => 2021-05-11 14:28:02 [post_content] => [post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => 2867 [to_ping] => [pinged] => [post_modified] => 2022-05-24 12:12:41 [post_modified_gmt] => 2022-05-24 12:12:41 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2867 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [250] => WP_Post Object ( [ID] => 2824 [post_author] => 5 [post_date] => 2021-04-16 16:39:49 [post_date_gmt] => 2021-04-16 16:39:49 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:31:21 [post_modified_gmt] => 2022-01-27 12:31:21 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2824 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [251] => WP_Post Object ( [ID] => 2823 [post_author] => 5 [post_date] => 2021-04-16 16:17:11 [post_date_gmt] => 2021-04-16 16:17:11 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5 [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:36:43 [post_modified_gmt] => 2022-01-18 12:36:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2823 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [252] => WP_Post Object ( [ID] => 2822 [post_author] => 5 [post_date] => 2021-04-16 16:09:31 [post_date_gmt] => 2021-04-16 16:09:31 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4 [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:48:13 [post_modified_gmt] => 2022-01-18 12:48:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2822 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [253] => WP_Post Object ( [ID] => 2820 [post_author] => 5 [post_date] => 2021-04-16 12:44:14 [post_date_gmt] => 2021-04-16 12:44:14 [post_content] => [post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2 [to_ping] => [pinged] => [post_modified] => 2022-01-18 12:50:08 [post_modified_gmt] => 2022-01-18 12:50:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2820 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [254] => WP_Post Object ( [ID] => 2744 [post_author] => 5 [post_date] => 2021-03-30 15:12:35 [post_date_gmt] => 2021-03-30 15:12:35 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12 [to_ping] => [pinged] => [post_modified] => 2021-08-12 13:48:08 [post_modified_gmt] => 2021-08-12 13:48:08 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2744 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [255] => WP_Post Object ( [ID] => 2749 [post_author] => 5 [post_date] => 2021-03-30 15:10:16 [post_date_gmt] => 2021-03-30 15:10:16 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11 [to_ping] => [pinged] => [post_modified] => 2021-08-12 13:54:16 [post_modified_gmt] => 2021-08-12 13:54:16 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2749 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [256] => WP_Post Object ( [ID] => 2748 [post_author] => 5 [post_date] => 2021-03-30 15:05:46 [post_date_gmt] => 2021-03-30 15:05:46 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => 2748 [to_ping] => [pinged] => [post_modified] => 2021-08-12 13:52:39 [post_modified_gmt] => 2021-08-12 13:52:39 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2748 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [257] => WP_Post Object ( [ID] => 2743 [post_author] => 5 [post_date] => 2021-03-24 15:11:40 [post_date_gmt] => 2021-03-24 15:11:40 [post_content] => [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:33:45 [post_modified_gmt] => 2022-01-27 12:33:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2743 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [258] => WP_Post Object ( [ID] => 2742 [post_author] => 5 [post_date] => 2021-03-24 13:37:07 [post_date_gmt] => 2021-03-24 13:37:07 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8 [to_ping] => [pinged] => [post_modified] => 2021-08-12 12:28:13 [post_modified_gmt] => 2021-08-12 12:28:13 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2742 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [259] => WP_Post Object ( [ID] => 2741 [post_author] => 5 [post_date] => 2021-03-24 13:32:55 [post_date_gmt] => 2021-03-24 13:32:55 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7 [to_ping] => [pinged] => [post_modified] => 2021-11-23 15:06:52 [post_modified_gmt] => 2021-11-23 15:06:52 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2741 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [260] => WP_Post Object ( [ID] => 2739 [post_author] => 5 [post_date] => 2021-03-24 13:12:14 [post_date_gmt] => 2021-03-24 13:12:14 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:47:55 [post_modified_gmt] => 2022-03-28 10:47:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2739 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [261] => WP_Post Object ( [ID] => 2737 [post_author] => 5 [post_date] => 2021-03-24 13:00:46 [post_date_gmt] => 2021-03-24 13:00:46 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4 [to_ping] => [pinged] => [post_modified] => 2021-08-12 12:45:35 [post_modified_gmt] => 2021-08-12 12:45:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2737 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [262] => WP_Post Object ( [ID] => 2736 [post_author] => 5 [post_date] => 2021-03-23 18:15:15 [post_date_gmt] => 2021-03-23 18:15:15 [post_content] => [post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3 [to_ping] => [pinged] => [post_modified] => 2021-12-03 14:50:37 [post_modified_gmt] => 2021-12-03 14:50:37 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2736 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [263] => WP_Post Object ( [ID] => 2734 [post_author] => 5 [post_date] => 2021-03-23 18:01:22 [post_date_gmt] => 2021-03-23 18:01:22 [post_content] => [post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine [to_ping] => [pinged] => [post_modified] => 2021-09-03 10:29:04 [post_modified_gmt] => 2021-09-03 10:29:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2734 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [264] => WP_Post Object ( [ID] => 2543 [post_author] => 5 [post_date] => 2021-03-12 18:15:58 [post_date_gmt] => 2021-03-12 18:15:58 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-01-04 18:43:53 [post_modified_gmt] => 2022-01-04 18:43:53 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2543 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [265] => WP_Post Object ( [ID] => 2540 [post_author] => 5 [post_date] => 2021-03-12 18:12:48 [post_date_gmt] => 2021-03-12 18:12:48 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-01-05 09:35:45 [post_modified_gmt] => 2022-01-05 09:35:45 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2540 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [266] => WP_Post Object ( [ID] => 2541 [post_author] => 5 [post_date] => 2021-03-12 18:11:14 [post_date_gmt] => 2021-03-12 18:11:14 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-05 10:49:36 [post_modified_gmt] => 2022-01-05 10:49:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2541 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [267] => WP_Post Object ( [ID] => 2542 [post_author] => 5 [post_date] => 2021-03-12 14:21:07 [post_date_gmt] => 2021-03-12 14:21:07 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-05 10:17:48 [post_modified_gmt] => 2022-01-05 10:17:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2542 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [268] => WP_Post Object ( [ID] => 2544 [post_author] => 5 [post_date] => 2021-03-12 14:16:06 [post_date_gmt] => 2021-03-12 14:16:06 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:10:55 [post_modified_gmt] => 2022-03-28 10:10:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2544 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [269] => WP_Post Object ( [ID] => 2545 [post_author] => 5 [post_date] => 2021-03-12 14:14:38 [post_date_gmt] => 2021-03-12 14:14:38 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7 [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:14:28 [post_modified_gmt] => 2022-03-09 13:14:28 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2545 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [270] => WP_Post Object ( [ID] => 2547 [post_author] => 5 [post_date] => 2021-03-12 13:58:55 [post_date_gmt] => 2021-03-12 13:58:55 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:38:40 [post_modified_gmt] => 2022-01-27 12:38:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2547 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [271] => WP_Post Object ( [ID] => 2549 [post_author] => 5 [post_date] => 2021-03-12 13:50:41 [post_date_gmt] => 2021-03-12 13:50:41 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-05 08:48:43 [post_modified_gmt] => 2022-01-05 08:48:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2549 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [272] => WP_Post Object ( [ID] => 2553 [post_author] => 5 [post_date] => 2021-03-12 13:47:42 [post_date_gmt] => 2021-03-12 13:47:42 [post_content] => [post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2 [to_ping] => [pinged] => [post_modified] => 2022-01-05 10:59:58 [post_modified_gmt] => 2022-01-05 10:59:58 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2553 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [273] => WP_Post Object ( [ID] => 2457 [post_author] => 5 [post_date] => 2021-02-25 15:25:57 [post_date_gmt] => 2021-02-25 15:25:57 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10 [to_ping] => [pinged] => [post_modified] => 2021-09-03 12:14:51 [post_modified_gmt] => 2021-09-03 12:14:51 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2457 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [274] => WP_Post Object ( [ID] => 2461 [post_author] => 5 [post_date] => 2021-02-25 15:23:35 [post_date_gmt] => 2021-02-25 15:23:35 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7 [to_ping] => [pinged] => [post_modified] => 2021-08-24 08:19:55 [post_modified_gmt] => 2021-08-24 08:19:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2461 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [275] => WP_Post Object ( [ID] => 2462 [post_author] => 5 [post_date] => 2021-02-25 15:23:19 [post_date_gmt] => 2021-02-25 15:23:19 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6 [to_ping] => [pinged] => [post_modified] => 2021-09-03 13:28:17 [post_modified_gmt] => 2021-09-03 13:28:17 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2462 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [276] => WP_Post Object ( [ID] => 2463 [post_author] => 5 [post_date] => 2021-02-25 15:22:52 [post_date_gmt] => 2021-02-25 15:22:52 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5 [to_ping] => [pinged] => [post_modified] => 2021-09-03 13:35:23 [post_modified_gmt] => 2021-09-03 13:35:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2463 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [277] => WP_Post Object ( [ID] => 2464 [post_author] => 5 [post_date] => 2021-02-25 15:21:51 [post_date_gmt] => 2021-02-25 15:21:51 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4 [to_ping] => [pinged] => [post_modified] => 2021-11-23 15:13:03 [post_modified_gmt] => 2021-11-23 15:13:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2464 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [278] => WP_Post Object ( [ID] => 2465 [post_author] => 5 [post_date] => 2021-02-25 15:21:32 [post_date_gmt] => 2021-02-25 15:21:32 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:40:25 [post_modified_gmt] => 2022-01-27 12:40:25 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2465 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [279] => WP_Post Object ( [ID] => 2466 [post_author] => 5 [post_date] => 2021-02-25 15:20:40 [post_date_gmt] => 2021-02-25 15:20:40 [post_content] => [post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:50:01 [post_modified_gmt] => 2022-03-28 10:50:01 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2466 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [280] => WP_Post Object ( [ID] => 2467 [post_author] => 5 [post_date] => 2021-02-25 15:20:15 [post_date_gmt] => 2021-02-25 15:20:15 [post_content] => [post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development [to_ping] => [pinged] => [post_modified] => 2022-03-09 13:15:33 [post_modified_gmt] => 2022-03-09 13:15:33 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2467 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [281] => WP_Post Object ( [ID] => 2470 [post_author] => 5 [post_date] => 2021-01-25 13:24:13 [post_date_gmt] => 2021-01-25 13:24:13 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14 [to_ping] => [pinged] => [post_modified] => 2022-03-28 13:54:22 [post_modified_gmt] => 2022-03-28 13:54:22 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2470 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [282] => WP_Post Object ( [ID] => 2473 [post_author] => 5 [post_date] => 2021-01-25 13:21:58 [post_date_gmt] => 2021-01-25 13:21:58 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12 [to_ping] => [pinged] => [post_modified] => 2022-01-04 14:14:59 [post_modified_gmt] => 2022-01-04 14:14:59 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2473 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [283] => WP_Post Object ( [ID] => 2474 [post_author] => 5 [post_date] => 2021-01-25 13:19:34 [post_date_gmt] => 2021-01-25 13:19:34 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11 [to_ping] => [pinged] => [post_modified] => 2022-01-04 12:54:44 [post_modified_gmt] => 2022-01-04 12:54:44 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2474 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [284] => WP_Post Object ( [ID] => 2475 [post_author] => 5 [post_date] => 2021-01-25 13:18:53 [post_date_gmt] => 2021-01-25 13:18:53 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10 [to_ping] => [pinged] => [post_modified] => 2022-01-04 11:57:00 [post_modified_gmt] => 2022-01-04 11:57:00 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2475 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [285] => WP_Post Object ( [ID] => 2476 [post_author] => 5 [post_date] => 2021-01-25 13:18:09 [post_date_gmt] => 2021-01-25 13:18:09 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9 [to_ping] => [pinged] => [post_modified] => 2022-01-04 12:42:48 [post_modified_gmt] => 2022-01-04 12:42:48 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2476 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [286] => WP_Post Object ( [ID] => 2477 [post_author] => 5 [post_date] => 2021-01-25 13:16:23 [post_date_gmt] => 2021-01-25 13:16:23 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8 [to_ping] => [pinged] => [post_modified] => 2022-03-08 13:38:40 [post_modified_gmt] => 2022-03-08 13:38:40 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2477 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [287] => WP_Post Object ( [ID] => 2479 [post_author] => 5 [post_date] => 2021-01-25 13:12:32 [post_date_gmt] => 2021-01-25 13:12:32 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6 [to_ping] => [pinged] => [post_modified] => 2022-01-27 12:42:15 [post_modified_gmt] => 2022-01-27 12:42:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2479 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [288] => WP_Post Object ( [ID] => 2481 [post_author] => 5 [post_date] => 2021-01-25 13:11:08 [post_date_gmt] => 2021-01-25 13:11:08 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4 [to_ping] => [pinged] => [post_modified] => 2022-01-19 10:39:14 [post_modified_gmt] => 2022-01-19 10:39:14 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2481 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [289] => WP_Post Object ( [ID] => 2482 [post_author] => 5 [post_date] => 2021-01-25 13:09:37 [post_date_gmt] => 2021-01-25 13:09:37 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3 [to_ping] => [pinged] => [post_modified] => 2022-01-04 14:23:50 [post_modified_gmt] => 2022-01-04 14:23:50 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2482 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [290] => WP_Post Object ( [ID] => 2471 [post_author] => 5 [post_date] => 2021-01-25 13:08:02 [post_date_gmt] => 2021-01-25 13:08:02 [post_content] => [post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement [to_ping] => [pinged] => [post_modified] => 2022-01-04 13:51:57 [post_modified_gmt] => 2022-01-04 13:51:57 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2471 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [291] => WP_Post Object ( [ID] => 2454 [post_author] => 5 [post_date] => 2021-01-19 11:44:16 [post_date_gmt] => 2021-01-19 11:44:16 [post_content] => [post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-5 [to_ping] => [pinged] => [post_modified] => 2021-11-23 14:28:26 [post_modified_gmt] => 2021-11-23 14:28:26 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2454 [menu_order] => 0 [post_type] => provision_document [post_mime_type] => [comment_count] => 0 [filter] => raw ) [292] => WP_Post Object ( [ID] => 2452 [post_author] => 5 [post_date] => 2021-01-19 11:41:19 [post_date_gmt] => 2021-01-19 11:41:19 [post_content] => [post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4 [to_ping] => [pinged] => [post_modified] => 2022-03-28 10:12:55 [post_modified_gmt] => 2022-03-28 10:12:55 [post_content_filtered] => [post_parent] => 0 [guid] => https://ghiaa.org/?post_type=provision_document&p=2452 [menu_order] => 0 [post_type] => provision_document [post_mime_type] =>